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Abstract
Characterization of the role of acetylated APE1 in DNA damage repair and
transcriptional regulation
Shrabasti Roychoudhury, Ph.D.
University of Nebraska Medical Center, 2019

Supervisor: Kishor K. Bhakat, Ph.D.
Apurinic/apyrimidinic (AP) sites are the most frequently formed DNA lesions in the
genome. The primary enzyme to repair AP sites in mammalian cells is the AP
endonuclease (APE1), which functions through the base excision repair (BER) pathway.
Mammalian APE1 has a unique N-terminal unstructured tail and has both DNA repair
and transcriptional regulatory activities. Our lab discovered that APE1 can be regulated
via post-translational acetylation of lysine residues 6, 7, 27, 31, and 32. The role of
mammalian APE1 in repair has been extensively studied and well characterized.
However, the regulatory role of APE1 acetylation (AcAPE1) in the context of both DNA
damage repair and transcriptional regulation has not been elucidated.
We show that APE1 is acetylated after binding to the AP sites in chromatin and
that AcAPE1 is exclusively present on chromatin throughout the cell cycle. Positive
charges of acetylable Lysine residues in the N-terminal domain of APE1 are essential for
chromatin association. Acetylation-mediated neutralization of positive charges of Lysine
residues in the N-terminal domain of APE1 induces a conformation change; this, in turn,
enhances the AP-endonuclease activity of APE1. In the absence of APE1 acetylation,
cells accumulated AP sites in the genome and showed higher sensitivity to DNAdamaging agents. Our study reveals that APE1 acetylation is an integral part of the BER
pathway for maintaining genomic integrity.
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By mapping genome-wide occurrence of endogenous AP site damages and
binding of repair proteins APE1 and AcAPE1, we demonstrate that oxidative base
damages predominantly occur in transcriptionally active regions, particularly Gquadruplex (G4) sequences and activation of APE1-mediated BER pathway promotes
the formation of G4 structures in the genome. Loss of APE1 or its acetylation abrogates
the formation of G4 structures in cells. Acetylation of APE1 enhances its residence time
and facilitates transcription factor loading, providing mechanistic insight into the role of
APE1 in G4-mediated gene expression. Our study unravels an acquired function of
endogenous base damage and AcAPE1-mediated BER in regulating transcription.
Together this study highlights role of AcAPE1 in coordinating potential functional
overlap between DNA damage repair activity and transcriptional regulation.
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CHAPTER 1

Introduction
Some of the material included in this chapter has been previously published:
Roychoudhury S, Pramanik S, Harris H and Bhakat k. K. “Biochemical and Cellular
Assays to Assess the Effects of Acetylation on Base Excision Repair Enzymes”.
Book chapter; Methods in Molecular Biology. 2019; 1983:191-206,doi: 10.1007/9781-4939-9434-2_11
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1.1 Overview of the base excision repair pathway
The genome is continuously challenged with endogenous and exogenous sources of
genotoxic agents such as cellular oxidative metabolism, exposure to chemicals, radiation
and cytotoxic drugs, resulting in oxidation, alkylation, and deamination-mediated base
damage (1-3). Base excision repair (BER) pathway is the predominant DNA damage
repair pathway for processing most of the base damages, single-strand breaks (SSBs),
and Apurinic/Apyrimidinic (AP) sites (4). AP sites are reported to be among the most
abundant type of DNA damage and can also occur as the result of spontaneous
hydrolysis of the N-glycosyl bond (5-7). If left unrepaired, AP sites can exert cytotoxic
effects by blocking DNA replication, and transcription, and can result in mutagenesis
through base substitutions, insertions, or deletions (8, 9). Due to the high frequency of
AP sites in the DNA and potential for promoting deleterious outcomes, in 1970s Lindahl
searched for possible repair activities specific for these lesions, discovered series of
enzymes and established BER pathway(5).
BER is a highly coordinated, multistep cellular process (10). There are several
damage-specific DNA glycosylases that initiates the BER pathway by excising modified
DNA base lesions (11). Two different types of lesion-specific DNA glycosylases,
monofunctional glycosylases that has only DNA glycosylase activity and bifunctional
glycosylases that has both DNA glycosylase and DNA strand cleavage activities have
been discovered (12). Monofunctional DNA glycosylase cleaves the damaged base and
creates an AP site. Subsequently, AP endonuclease 1 (APE1) recognizes the AP site,
cleaves the DNA backbone, and this results in the formation of a one nucleotide gap
flanked by 3′-hydroxyl and 5′-deoxyribose-phosphate (5′-dRP) end which is recognized
by the downstream enzyme DNA polymerase β (pol β). On the other hand, bifunctional
DNA glycosylases, along with base damage removal, incise the DNA backbone to create
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a single-nucleotide gap flanked by either a 5′ phosphate and a 3′-α,β-unsaturated
aldehyde (termed β-elimination) or 5′-phosphate and 3′-phosphate residues (termed β,δelimination). 8-oxoguanine (8-oxoG) DNA glycosylase (OGG1) and the endonuclease III
homolog (NTH1) are known to catalyze β-elimination, creating "dirty ends". Following
their activity, the 3′-α, β-unsaturated aldehyde is excised by APE1 to generate a "clean"
3′-hydroxyl end, which is the same product resulted from monofunctional DNA
glycosylase and APE1 action (13). After APE1’s action, Pol β hydrolyzes the 5′dRP
moiety and fills the single nucleotide gap by incorporating a complementary base (14,
15). Finally, DNA ligase IIIα (Lig III) and X-ray cross-complementing protein 1 (XRCC1)
together seals the remaining nick in the DNA backbone (16). This pathway is known as
short-patch BER (Fig. 1) (17). Alternatively, when the 5′-dRP residue is oxidized or
reduced and resistant to excision by Pol β, series of (typically 2 to 8) nucleotides into the
single-nucleotide gap is added, generating a 5′-DNA flap structure (18). This flap is
excised by flap endonuclease-1 (FEN-1) in a proliferating cell nuclear antigen (PCNA)dependent process. Finally, DNA ligase I (Lig I) in the presence of PCNA seals the
remaining nick in the DNA backbone completing long-patch BER pathway (19). Overall,
BER relies on sequential recruitment and coordinated actions of multiple proteins via a
series of transient repair complexes that assemble at the site of the DNA lesion (20).
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Figure 1: Schematic of the BER pathway. Base excision repair (BER) is initiated by a
damage specific DNA glycosylase that excises the damaged base to create an AP site,
which is then incised by APE1 creating a DNA SSB flanked by 3′-hydroxyl and 5′-dRP
ends. Pol β cleaves the 5′-dRP moiety and simultaneously adds a single correct
nucleotide into the one-nucleotide gap. Finally, the DNA SSB ends are sealed by the
XRCC1-Lig IIIα complex.
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1.2 Overview of APE1 biology
Human apurinic/apyrimidinic endonuclease 1 (APE1) is a multifunctional protein playing
a pivotal role in not only the removal and repair of numerous DNA lesions through its
endonuclease function, but also as a redox activator of numerous transcription factors,
including Egr1, NF-κB, p53, and HIF1a and as a direct transcription regulator through its
N-terminal tail domain (7, 21, 22). Although functionally independent, all three functions
are important for cell survival (7, 23).
In

the

early

1990s,

the

transcript

encoding

the

human

AP

endonuclease

(apurinic/apyrimidinic endonuclease 1 (APE1/APEX1)) was cloned by the Demple,
Hickson, and Seki groups (24). Surprisingly, around the same time, human APE1 was
independently identified by Curran and colleagues as the major nuclear protein (termed
REF-1) to simulate the DNA-binding activity of the AP-1 (Fos/Jun) transcription factor
complex (25, 26). This activation was shown to be mediated through reduction of a
conserved cysteine residue within the DNA binding domain of the target protein and was
also observed with factors such as NF-κB, Myb, and members of the ATF/CREB family
(22, 26-28). Soon after, Okazaki's group demonstrated that APE1 could directly bind to
negative Ca2+ response elements (nCaREs) and modulate gene expression. Thus,
acting as a direct trans-acting factor (29). Of note APE1-nullizygous mice are early
embryonic lethal, and that no APE1-null mouse embryo fibroblast (MEF) line could be
established (30).
The human APE1 gene is located on chromosome 14q11.2 and ubiquitously
expressed in all tissue and cell types from a housekeeping-like promoter (7). It encodes
a protein of 318 amino acids (theoretical molecular weight of 35.5 kDa) (7). Unlike its
E.coli counterpart Xth, mammalian APE1 has acquired a unique, unstructured, highly
positively charged 60-amino acid region in the N-terminal, which also houses the

6

consensus nuclear localization signals (NLSs) (31) . While the C-terminal part of the
protein is highly conserved, the N-terminus is not. Mammalian APE1 has highly
conserved (>90%) N-terminus, this region is almost always absent in other organisms.
X-ray diffraction and site-directed mutagenesis have revealed that APE1 is composed of
a rigid globular C-terminal nuclease domain and a highly disordered N-terminal domain
(32, 33). The N-terminal domain is responsible for the transcription regulatory activity of
APE1 and is thought to additionally mediate alternative APE1 functions and/or its
protein-protein interactions, whereas the C-terminal domain is responsible for DNA
binding and backbone cleavage activity (34, 35).

1.2.1 Biochemical functions of APE1:
APE1 as a nuclease: APE1 is known as a skilled nucleic-acid surgeon, exhibiting
endonuclease, 3′ phosphodiesterase, 3′ to 5′ exonuclease, and RNA cleavage activities
(36). Most well-characterized role of APE1 is that it cleaves the DNA phosphodiester
backbone at the 5′ termini of the AP site, generating a nick in the DNA with 3′ hydroxyl
and 5′ dRP termini (37). There is a consensus that the D210 and H309 amino acid
residues have critical functions in the hydrolytic reaction chemistry, and E96 plays a role
in divalent metal coordination (32, 34). Other important residues include N68, D70,
Y171, N212, D283, and D308, which are generally conserved throughout the diverse
members of the phosphoesterase superfamily (32). Experiments using human whole cell
extracts have shown that APE1 functions in the rate-limiting step of the BER pathway
(38). The pre-steady state kinetic description of strand incision at AP sites by APE1 is
that rapid catalysis is followed by slow product release. This rapid catalysis is vital for
genomic stability given the prevalence of AP sites in the genome, while the slow
catalysis step has been proposed to conceal cytotoxic BER intermediates during DNA-
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damage processing and facilitate coordination with the next enzyme in the BER
pathway.
APE1 as a Redox-signaling factor: Besides serving in a crucial role in the
maintenance of genome stability through its endonuclease activity, APE1 also acts as a
master regulator of cellular response regulating redox signaling activity (22). APE1; also
known as REF-1, reduces oxidized cysteine residues of specific transcription factors as
part of their transactivation process. REF-1 regulates numerous transcription factors,
including nuclear factor kappa B (NF-κB), STAT3, HIF-1α, AP-1, p53 (39-42). Although
the repair function has been conserved from E. coli to humans; the redox signaling
function is observed only in mammals (43). Among seven Cystine (Cys) residues
APE1/Ref-1, three of the Cys residues, C65, C93, and C99, are sufficient for its redox
activity (43). The mechanism involves a redox cycle with potential formation of
intermolecular disulfide bonds with the protein target (44, 45). Structural studies
demonstrated that APE1 exists in both native and partially unfolded conformations (46).
The partially unfolded state of APE1 represents the redox active intermediate of the
enzyme, which can be targeted by the APE1 redox inhibitor APX3330 (formerly E3330)
(47). APX3330 stabilizes the unfolded state causing buried Cys residues such as C65
and C93 to be exposed and facilitates disulfide bond formation. This disulfide bond
formation results in inactivation of APE1 and a decrease in interaction with downstream
transcription factors effectively causing them to be inactive. APX3330 has shown to be a
selective inhibitor of REF-1/APE1 redox activity with minimal cytotoxic effect and moved
to a successful clinical trial (48, 49). APE1/ REF-1 is viewed as a critical node in many
important signaling pathways and thus is a prime target for anticancer therapy (39).
Transcription regulatory function of APE1: Okazaki’s group first established a Redox
independent transcription regulatory role of APE1 as they identified APE1 as one of the
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proteins that bind to negative calcium response elements (nCaRE) complex in the
human PTH gene promoter and regulate PTH expression (29). Subsequently, a nCaREB sequence, identical to that in the PTH promoter, in the human renin gene has been
identified (50). Involvement of this element and binding of APE1 in Ca2+-mediated
repression of renin gene expression has been shown by promoter-driven reporter assay
system in cells. Interestingly, Jayaraman et al. showed that recombinant APE1 can
stimulate DNA binding of full-length p53, which was further strongly stimulated in the
presence of DTT, indicating that APE1-mediated activation of P53 might be independent
of its function as a redox activator (51). In a separate study Egr-1, a transcription factor
with tumor suppressor function was shown to stably interacts with APE1 and treatment
with H2O2 strongly stimulates their association and increases Egr-1's DNA-binding
activity in cells to regulate expression of many genes, including p53 and PTEN (52).
APE1's interaction with HIF-1α and p300 was found to be critical for the assembly of the
hypoxia-inducible transcriptional complex on the hypoxic response element (HRE) in the
VEGF gene promoter in the rat pulmonary artery endothelial cells (53). Gray et al.
showed that APE1 along with CBP/p300 associates with STAT3 and HIF-1α at the
VEGF promoter, where they form an active transcriptional complex that regulates Srcdependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinoma
(54). Our studies highlighted that APE1-YB1 complex binds to MDR1 gene promoter and
activates gene expression (55). Importantly, redox-inactive Cys65Ser and Cys138Ser
APE1 mutants behaved same as WT APE1 in modulating YB-1-mediated MDR1
promoter activity, suggesting that APE1's redox activity is not involved in MDR1
activation. Together, all these studies demonstrating redox-independent transcriptional
function of APE1 in modulating HIF-1α, Egr-1, and YB-1 activities established the third
role of APE1 as a trans-acting factor.

APE1’s presence in diverse trans-acting
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complexes requires interaction with diverse partners, which can be possible through its
N-terminal unstructured tail domain. Various studies have observed deletion of Nterminal 30 aa or neutralizing positive charge of Lysine residues abrogates proteinprotein interaction and affects gene expression (31, 56, 57). However, the detailed
molecular mechanism by which APE1 regulates gene expression as a co-transcription
factor is still unclear.

1.2.2 Post-translational regulation of APE1 by Acetylation:
The activity of a single protein with pleiotropic functions could be "fine-tuned” via posttranslational modifications, including phosphorylation, acetylation, ubiquitination, and
methylation, in order to coordinate specific biological activities. Research on disordered
regions of proteins have revealed that due to the lack of structure and increased
malleability, disordered regions can act as a hub for modulating protein interactions and
are highly susceptible to post-translational modifications (PTMs) (58). Given the multiple
functions, it is not surprising that APE1 is post-translationally modified in vivo (59). The
cross talk between different post-translational modifications and different function of
APE1 is yet to be fully characterized. Increasing evidence suggests that many of the
proteins that participate in BER can be acetylated, as determined by in vitro analysis of
purified proteins or cell extracts and in vivo analysis (Fig. 2) (60-64). Acetylation
provides increased specificity and efficiency to the BER pathway. Acetylation can alter
the binding characteristics, turnover rates, subcellular localization, and the overall
efficacy of the target protein.
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Figure 2: A schematic representation of steps involved in the BER pathway.
Acetylation of multiple enzymes facilitates sequential processing of BER intermediates.
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Our lab has discovered that Lysine 6 and 7 residues in mammalian conserved N terminal domain of APE1 can undergo acetylation by the histone acetyltransferase p300
both in vitro and in vivo (56, 65). Mass spectroscopic analysis of in vitro acetylated APE1
(AcAPE1) could not detect diacetylated molecule suggesting possible due to steric
effects of acetyl groups attached to ɛ-amino groups during the second acetylation. Thus,
either Lys6 or Lys7 but not both can be acetylated in the same molecule. Generation of
affinity-purified AcAPE1-specific antibody using a human APE1 peptide with acetylated
Lys6 and showed that the AcAPE1 antibodies are highly specific for AcAPE1, and do not
cross-react with at least 25-fold excess unmodified APE1 (55). Moreover, this antibody
recognizes ectopic FLAG-tagged WT APE1, but not non-acetylable K6R/K7R APE1 in
cell extracts confirming its specificity for AcAPE1.Importantly, the presence of
endogenous AcAPE1 in cells was confirmed using this antibody. Although the first 20
amino acid residues contain the consensus nuclear localization signal (NLS) sequence
(MPKRGKK) that includes the acetylation sites, acetylation of K6 and K7 of APE1 is not
involved in its nuclear localization (66). Importantly, APE1 acetylation stimulates the
formation of the nCaRE-B complex at PTH promoter, activates Egr-1 dependent PTEN
expression, and promotes YB-1 binding at MDR1 promoter (55, 56, 67, 68). H. pylori
infected gastric cells induces AcAPE1 that promote binding at nCARE element and
regulation of Bax gene (69). Later, Tell group in collaboration with our lab discovered
that APE1 can also be acetylated at lysine residues 27, 31, and 32 along with 6 and 7
and acetylation is regulating transcription regulatory function (62). They showed, Lys 27,
31, and 32 acetylation is dependent on Lys 6 and 7. However, cellular dynamics
between acetylation sites, spatiotemporal regulation, and functional importance of
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acetylation sites is not clear. Of Note, HDCA1 and SIRT1 is responsible for APE1
deacetylation in cells (70, 71).
AcAPE1 levels are enhanced in primary tumor tissues of diverse background (57,
71). Our lab discovered that acetylation APE1 (AcAPE1) enhances endonuclease
activity and regulates transcription of genes including, Multi-Drug Resistance gene
(MDR1), via loading of transcription factors (67). Importantly, both the DNA repair
domain and acetylable Lys6 and 7 residues of APE1 are essential in cell proliferation
and survival in conditional APE1-nullizygous mouse embryo fibroblast (MEF) cells, (72).
Furthermore, a recent study showed that the absence of acetylation at Lys 6/7 sites in
APE1 or its DNA repair function resulted in telomere fusion and mitotic defects (73).
Given the key role of APE1 in the repair of AP sites, which inhibits replication and
transcription, the importance of the DNA repair function of APE1 is not surprising.
However, the essentiality of the acetylable Lys residues for mitotic progression and cell
proliferation were unexpected.
Acetylation of APE1 protects APE1 proteolysis, by a serine protease, following
residue lysine (Lys) Lys6 and/or Lys7 and after Lys27 and Lys31 or Lys32 at its Nterminus in the tumor tissue (57). The N-terminal domain of APE1 and its acetylation
modulates its AP-endonuclease activity and is important for regulation of the expression
of hundreds of genes and essential for sustained cell proliferation and/or survival (57,
71). Elucidating the mechanisms by which N-terminal acetylation modulates the
essential DNA repair and transcriptional regulatory functions in vivo that promote cell
survival and cell proliferation is extremely important to understand the role of AcAPE1 in
tumorigenesis. It is possible that acetylation-mediated conformational change in the
disordered N-terminal segment (encompassing 40 aa residues), modulates protein-
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protein interaction and thus regulates its DNA repair and co-transcription regulatory
function.

1.3 Objectives of the dissertation:
The role of mammalian APE1 in repair has been extensively studied and well
characterized. However, the regulatory consequences of APE1 acetylation in the context
of both DNA damage repair and transcriptional regulation has not been elucidated.
The overall objectives of my dissertation research are,
 Investigate the spatiotemporal sub-cellular and genome-wide distribution of
AcAPE1 and non-modified APE1.
 Characterize unique and divergent role of AcAPE1 to that of non-modified APE1,
which can help to understand the role of AcAPE1 in cell proliferation.
 Elucidating the role of AcAPE1 in the BER pathway.
 Delineate the molecular mechanism by which AcAPE1 regulates gene
expression.
 Investigate potential functional overlap between DNA damage repair activity and
transcriptional regulation coordinated by AcAPE1.

This dissertation research aims to characterize the role of AcAPE1 in mammalian cells.
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CHAPTER 2

Human AP-endonuclease (APE1) is acetylated at DNA damage
sites in chromatin and acetylation modulates its DNA repair
activity

The materials presented in this chapter has been previously published: Roychoudhury S,
Nath S, Song H, Hegde M, Bellot L, Mantha A, Sengupta S, Ray S, Natarajan A and
Bhakat k.K. “Human AP-endonuclease (APE1) is acetylated at DNA damage sites in
chromatin and acetylation modulates its DNA repair activity”. Molecular and Cellular
Biology, MCB, DOI:10.1128/MCB.00401-16.
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2.1 Introduction
Common forms of DNA damage in the genome are apurinic/apyrimidinic (AP) sites (5,
74). AP sites can be generated either spontaneously through water-mediated
depurination or depyrimidination or after removal of oxidized and modified bases by DNA
glycosylases (5). Thousands of such AP sites are daily generated in the genome of a
human cell (74). These noninstructional AP sites are mutagenic and can inhibit DNA
replication and transcription (9, 75) . The primary enzyme to repair AP sites in
mammalian cells is the AP endonuclease (APE1), which functions through the Base
Excision Repair (BER) pathway (76, 77). Human APE1 is a ubiquitous and
multifunctional protein (76). It was originally discovered as a DNA repair enzyme playing
a central role in the repair of spontaneously generated AP sites and oxidative and
alkylated DNA damages in the genome via the BER pathway (4, 24, 77). Apart from its
DNA repair function, APE1 functions as a redox activator of many transcription factors
(TFs), as well as a direct transcriptional co-regulator of many genes (31, 40).
APE1 is essential for embryonic development and for cell viability and or proliferation in
cultures (26, 72, 78). Unlike its E. coli prototype Xth, Human APE1 is unique in that it
has an N-terminal disordered 42 amino acid (aa), and has both DNA repair and
transcriptional regulatory activities (31). In previous studies, we discovered that APE1
can be acetylated (AcAPE1) at multiple Lysine (Lys) 6 and Lys 7 residues in the Nterminal domain, and that acetylation modulates the transcriptional co-regulatory activity
of APE1 (56, 67). Moreover, Dr. Tell’s group in collaboration with us found that other Lys
residues (Lys,27,31,32 &35) in the N-terminal domain of APE1 can be modified by
acetylation and these Lys residues modulates nucleolar localization and BER activity of
APE1(62). We have recently shown that tumor tissue of diverse cancer types have
elevated levels of AcAPE1 (57). APE1 was also shown to be ubiquitynated at Lys 24,25
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and 27 residues (79). Further, using conditional APE1-nullizygous mouse embryo
fibroblasts (MEF), we showed that acetylable Lys6 and Lys7 residues of APE1 are
essential for cell survival (72). The acetylation sites are conserved in most mammalian
APE1(31), suggesting that evolutionary conservation or neutralization of the basicity of
these Lys residues by acetylation in the N-terminal domain has essential biological
functions. Over the last 20 years, the mechanisms by which AP sites are repaired by
APE1 in vitro via BER pathway have been extensively investigated (15, 32, 80-82).
However, it is largely unknown how APE1 repairs AP sites in mammalian cells.
In this study, we show that APE1 is acetylated after binding to the AP sites in the
chromatin and that AcAPE1 is exclusively associated with chromatin throughout the cell
cycle. Further, our study revealed the key role of positive charges of the acetylable Lys
residues for nuclear localization of APE1 and its binding to chromatin. APE1 acetylation
induces a conformation change in APE1 which enhances the AP-endonuclease activity
of APE1 and its interaction with downstream BER proteins. Our study shows that
acetylation of APE1 plays a crucial role in the repair of AP sites and oxidative and
alkylated base damages in the genome and thus promotes cell survival and proliferation.

2.2 Materials and methods

Cell lines, plasmids, siRNAs, transfection and treatments: Human embryonic kidney
HEK-293 (ATCC # CRL-1573) and inducible APE1-downregulated HEK-293TAPE1siRNA
cells were cultured in DMEM-high glucose medium (Thermo Fisher scientific) with 10%
fetal calf serum (FCS; Sigma) and antibiotic mixture of 100 U/ml penicillin and 100 µg/ml
streptomycin (Gibco-BRL) as described previously (67). Human Colon cancer HCT116
(ATCC #CCL-247) was grown in MaCoy 5A medium (Thermo Fisher scientific).
Generation of HCT116 cells stably expressing APE1-shRNA or control shRNA were
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described previously (83) . hTERT-immortalized human foreskin fibroblast BJ-5ta (ATCC
#CR-4001), Normal lung fibroblast IMR-90 (ATCC# CCL-186), Lung adenocarcinoma
A549 (ATCC# CCL-185), cells were cultured in DMEM-low glucose medium (Thermo
Fisher scientific) with FCS and antibiotics. All cell lines were authenticated by STR DNA
profiling on August, 2015 by Genetica DNA laboratories, Burlington, NC. Mutation of Lys
residue (K6,7,27,31 and 32) singly or in combination to arginine or to glutamine or to
Alanine in APE1-FLAG-tagged pCMV5.1 plasmid were generated using a site-directed
mutagenesis Kit (Agilent, Stratagene) following manufacturer’s protocol. Exponentially
growing HCT116 cells stably expressing APE1-shRNA cells were transfected with wild
type (WT) APE1, K6,7,27,31,32 to arginine (K5R) or to glutamine (K5Q) mutants
expression plasmids. In another set of experiment, HEK-293TAPE1siRNA cells were treated
with Doxycycline (1ug/ml) for 5 days to knockdown the APE1 levels then cells were
transfected with FLAG-tagged WT APE1 or K5R or K5Q or N-terminal 33 amino acid
deleted (N∆33) mutants APE1 as described elsewhere (55, 67, 84, 85). Expression
plasmid Adenovirus EIA12S and the mutant E1A (2-36 amino acid deletion) were
described earlier (86). Cells were transfected using Lipofectamine 2000 (Invitrogen) and
harvested after 48 hrs. Methoxyamine, Glucose oxidase and Methyl Methanesulfonate
were obtained from Sigma.
Immunofluorescence and Proximal Ligation Assay (PLA): Different types of cells
(HEK-293, HCT116, A549, BJhTERT, IMR-90) were grown on coverslips.

After

transfection with indicated plasmids cells were fixed with 4% formaldehyde (Sigma) for
20 minutes and permeabilized with 0.2% Triton X-100 (Sigma) containing blocking
solution (goat serum, glycine, sodium azide) for 1 hour. Slides were incubated overnight
at 4°C with the primary antibodies, washed three times with PBS, and incubated with the
secondary antibodies Alexa Fluor 488 anti-mouse IgG (Life technologies, 1:500) or
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Alexa Fluor 594 anti-rabbit IgG (Life Technologies; 1:500) at room temperature for 1 h.
After washing three times, slides were mounted on Vectashild-DAPI containing media
(Vector Laboratories). Primary antibodies used for immunofluorescence studies were
mouse monoclonal anti-APE1 (1:100; Novus Biologicals; # NB100-116), anti-AcAPE1
(1:50; (55)), Anti-FLAG(1:50; Sigma; #F3165), Anti-p300(1:100; Activemotif; #61401 ),
Anti-OGG1 (1:50), Anti-Histone H3 (1:100; Santa Cruz; #sc10809), Anti-H3K27
aetylated histone (1:100; Milipore; #05-1334), Anti-Ligase III (1:50; Novus Biologicals;
#NB100-152) Anti-Lamin B (1:50; Abcam; #ab16048) . PLA was performed following the
manufacturers protocol (Duolink® In Situ – Fluorescence PLA technology, Sigma).
Numbers of signal for co-localization of these two molecules were calculated using the
Duolink PLA software. For the quantification at least 50 cells nuclei were counted for
each experiment, and SDs from three independent experiments were calculated. Images
were acquired by fluorescence microscope, 63X-oil (Zeiss LSM 510) and Structured
Illumination Microscopy (SIM) was done with a Zeiss Elyra PS.1 Microscope (Carl Zeiss)
by using a 63× objective with NA of 1.4. To measure colocalization, ImageJ was used to
measure Manders colocalization using the JaCoP plug-in.

Isolation of cytoplasmic, nuclear and chromatin fractions and Western blot
analysis: Cells were lysed in cytosol extraction buffer (Tris-HCl pH8 10mM, Sucrose
0.34mM, CaCl2 3mM, MgCl2 2mM, EDTA 0.1mM, DTT 1mM, Nonidet P-40 0.1%,
Protease inhibitor cocktail). After centrifugation, the supernatant was collected as
cytoplasmic fraction. The pellet was then dissolved in nuclear extraction buffer (HEPES
pH 7.9 20mM, EDTA 3mM, Glycerol 10%, Potassium acetate 10mM, Magnesium
chloride 1.5mM, DTT 1mM, Nonidet P-40 0.5%, Protease inhibitor cocktail) and collected
as nuclear fraction. Finally, the pellet was dissolved in chromatin extraction buffer
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(HEPES 150Mm, Mgcl2 1.5Mm, potassium acetate 150mM, Glycerol 10%, Protease
inhibitor cocktail), 4 U nuclease (DNase and RNase) was added and incubated for 30
minutes at 37ºC. After centrifugation the supernatant was collected as chromatin
fraction. The whole cell lysates were prepared with cold lysis buffer containing 50 mM
Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1 mM EDTA and protease inhibitor
cocktail buffer tablet (PI; Roche Diagnostics) resolved by SDS/PAGE. Various primary
antibodies (Ab) used are mouse monoclonal α-APE1 (Novus), α-FLAG (sigma), αHSC70 (B6-Sc7298, Santa Cruz Biotechnology), α-α-Tubulin (Sigma: # T6199) Abs,
AcAPE1, mSin3a (Santa Cruz; #sc994).
Apurinic/apyrimidinic (AP) endonuclease activity assay: A 43-mer oligonucleotide
containing AP site analog tetrahydrofuran (THF) at nucleotide 31 (Midland Corp) was 5′end-labeled with [γ-32P]ATP using T4 polynucleotide kinase as described previously (31,
87, 88). Following annealing to the complementary strand with an opposite THF, the
duplex oligomer was purified by gel filtration column (Chroma Spin TE 10; Clontech).
This THF-containing duplex oligomer was incubated with recombinant WT-APE1 or
recombinant AcAPE1, prepared as described earlier (55, 67) at 37º C for 3 min during
which the reaction rate was linear in a 15 μL reaction mixture containing 50 mM Tris-HCl
pH 8.5, 50 mM KCl, 1mM MgCl2, 1 mM DTT, 0.1 mM EDTA and 100 μg/mL bovine
serum albumin. The reaction was stopped with 10 μl 80% formamide/40 mM NaOH
containing 0.05% xylene cyanol, followed by heating at 95°C for 5min. The samples
were ran in a denaturing gel electrophoresis in 20% polyacrylamide containing 8M urea
to separate the substrate oligomer from the cleaved product. The gels were dried and
the radioactivity was quantitated by phospho-imager analysis in a Storm system
(Molecular Dynamics). The kinetic parameters Km and kcat were calculated by incubating
33 pM enzyme at 37°C for 3 min with substrates at various concentrations (0-160 nM).
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The enzyme kinetics data were fitted by nonlinear least-squares regression to obtain
Vmax and Km with the Michaelis–Menten equation using Sigma plot software.
AP site measurement assay: After endogenous APE1 downregulation in HEK293TAPE1siRNA cells with Dox treatment, the cells were transfected with WT or mutant
APE1 expression constructs, as described above. 48 hrs. post transfection, cells were
treated with or without glucose oxidase for 30 min and total genomic DNA was isolated
by Qiagen Dneasy kit following manufacturer’s protocol. AP sites were measured using
aldehyde reactive probe (Dojindo Laboratories) according to manufacturer’s protocol.
UV fluorescence: The recombinant APE1 or AcAPE1 protein solution in PBS buffer (pH
7.5) were excited at 280 nm at 25ºC, emission was monitored at 300-450nm. The
average spectrum was obtained from triplicate measurement.

Chromatin

Immunoprecipitation

assay

and

ChIP-on-Western:

chromatin was immunoprecipitated with anti-AcAPE1 antibody and

Cross-linked
p21 promoter

directed ChIP analysis was carried out essentially as described previously (85). ChIPon-Western was performed as described (89) using anti-OGG1.

Colony forming assay: Generation of HEK-293TAPE1siRNA cell line stably expressing
APE1 siRNA from a doxycycline-inducible promoter HEK-293T (HEK-293TAPE1siRNA) cells
were described earlier (67). HEK-293TAPE1siRNA cells were treated with doxycycline
(Sigma; 1 µg/ml) for 5-6 days to knockdown endogenous APE1 and transfected with
expression plasmids containing WTAPE1 or different APE1 mutants. Equal numbers
(Approximate 500) of cells plated on 60 mm plates were treated with or without glucose
oxidase (100 ng/ml for 30 min). After washing fresh medium was added and cells were
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allowed to grow for two weeks until visible colonies appear. The colonies were fixed with
100% methanol, stained with Giemsa staining solution (1:50) and counted. HCT116 cells
stably expressing APE1 shRNA were transfected with WTAPE1 or APE1 mutants. 48
hrs after transfection approximately 500 cells on 60-mm dishes were treated with various
doses of Methyl Methanesulphonate, MMS (0.5, 1, 1.5 and 2mM) for 1hrs and then
washed and fresh medium was added to grow for two weeks until visible colonies
appear. HCT116 cells expressing control shRNA used as a control.

2.3 Results:
AcAPE1 is exclusively associated with chromatin throughout cell cycle.
We investigated the sub-cellular localization of AcAPE1 using our previously
characterized AcAPE1 antibody (Ab) (55, 67). We showed earlier that this AcAPE1 Ab is
highly specific for recognizing APE1 species acetylated at the N-terminal Lys6 residue
and does not cross-react with 50-fold excess of unmodified APE1 (55). Moreover, this
Ab was unable to recognize ectopic APE1 molecules with mutated Lys6 residues (31).
Confocal microscopy and super resolution (110 nM) 3D Structured Illumination
Microscopy (SIM) data

revealed AcAPE1 staining to be strictly nuclear, whereas

unmodified APE1 was observed both in the nucleus and cytoplasm in human normal
lung fibroblasts (IMR90) cells, hTERT-transformed diploid BJ fibroblast cells, as well as
human lung adenocarcinoma A549 cells (Fig. 1A,1B and 1D). Using chromatin marker
histone H3 or active enhancer marker H3K27Ac Abs, we found that AcAPE1 is present
on chromatin (Fig. 1C). Furthermore, Structured Illumination Microscopy (SIM) revealed
that AcAPE1 is exclusively localized in the chromatin (Fig. 1B). As chromatin can be
easily observed during cell division in mitosis, we examined AcAPE1 localization in
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mitotic cells. AcAPE1 was found to be exclusively localized to the condensed chromatin
at all stages of mitosis, from prometaphase to telophase in both fibroblast cells and in
cancer cells (Fig. 1D and 1E). Exclusive association of AcAPE1 on chromatin was also
confirmed by Proximal Ligation Assay (PLA) using APE1 or Histone H3 and AcAPE1
Abs (Fig. 1G). Our data show higher PLA signal localized on DAPI. Consistent with this,
biochemical extraction of proteins with different salt concentration demonstrated a higher
proportion of AcAPE1 in high salt fractions at different stages of cell cycles (Fig. 1F). We
demonstrated earlier that p300 is the primary acetyltransferase for acetylating APE1
(67). We observed that AcAPE1 co-localizes with p300 only on chromatin (Fig. 1H).
Furthermore, overexpression of E1A12S, which was shown to bind p300 and inhibit its
HAT activity (86), significantly reduced AcAPE1 staining, but not APE1 staining in cells
(Fig. 1I), further confirming the specificity of our AcAPE1 Ab. Overexpression of E1A
deletion mutant 2-36, which cannot bind to p300, had no effect on AcAPE1 staining (Fig.
1I). Together these data suggest that APE1 is acetylated by p300 and that AcAPE1 is
exclusively associated with chromatin in cells.
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Figure 1: AcAPE1 is exclusively associated with chromatin and remains bound to
the condensed chromosomes. (A & B) Asynchronous normal lung fibroblast IMR-90
cells and lung adenocarcinoma A549 cells were immunostained with α-APE1 and αAcAPE1 Abs, and counter stained with DAPI and visualized by Confocal microscopy and
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3D Structured Illumination Microscopy (SIM). (C) Co-localization of AcAPE1 with Histone
H3 or active enhancer- specifichistone marker, H3K27Ac. (D) BJ-hTERT cells were
serum starved for 72 hrs, and then fixed at different time points. Cells were
immunostained with α-APE1 and α-AcAPE1 Abs, and counterstained with α-TO-PRO-3
iodide Ab. (E) Mitotic A549 cells were immunostained with α-APE1 and α-AcAPE1 and
visualized by 3D SIM. (F) BJ-hTERT cells were either serum starved for 72 hrs (G0/G1),
or treated with nocodazole (mitotic), or aphidicolin (G1/S synchronized cells) or
untreated and whole cell extracts were isolated using 150mM or 300mM salt containing
lysis buffer. Western blot analysis for α-APE1 and α-AcAPE1 levels was performed. αHSC70 was used as loading control. (G) Proximal Ligation assay was performed with αAPE1 mouse (mAPE1) & α-APE1rabbit (Rabbit-APE1), α-mAPE1& α-rAcAPE1(rabbitAcAPE1) and α-rAcAPE1& α-mHistone H3 (mouse-Histone H3) to confirm the chromatin
association of AcAPE1. Mouse IgG (mIgG) & α-rAcAPE1 were used as a control. At
least 50 cells were counted for PLA foci. (H) Co-localization of p300 and AcAPE1 on
chromatin (DAPI). (I) HCT116 cells were transfected with E1A and mutant E1A (mE1A)
and 48 hours after transfection Immunofluorescence assay (IF) was performed. Cells
were immunostained with α-p300 and α-APE1 or α-AcAPE1 and counterstained with
DAPI.
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Positive charges of acetylable Lys residues but not their acetylation are essential
for chromatin-binding of APE1.
To test if acetylation of APE1 is essential for association with chromatin, we generated
several site-specific acetylable Lys mutants and performed localization studies using
immunofluorescence (Fig. 2A) and biochemical fractionation assays (Fig. 2C). We found
that mutations of Lys6,7 or Lys27, or Lys6,7,27 or all five acetylable Lys
(Lys6,7,27,31&32, (K5R)) residues to non-acetylable Argnine, which maintains positive
charges but cannot be acetylated, did not affect the chromatin association of APE1 (Fig.
2A). Surprisingly, neutralization of positive charges of Ly6,7 or Lys27 or Lys6,7,27 or all
five acetylable Lys residues to Glutamine (K5Q) or Alanine (K5A) had a drastic effect on
the chromatin binding of APE1 (Fig. 2A), and showed perinuclear localization of APE1
(Fig. 2B). Our biochemical fractionation assay shows that neutralization of positive
charges of these Lys residues significantly affected chromatin association of APE1 (Fig.
2C). We also used APE1 H309N mutant which was shown to be catalytically (APendonuclease activity) inactive, but can bind to an AP site substrate (90). We found that
the H309N mutant can associate with chromatin similarly as WT APE1 (Fig. 2A).
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Figure 2: Positive charges of acetylable Lys residues but not their acetylation are
essential for chromatin-binding of APE1.(A) Cells expressing different Lys sitespecific APE1 mutants were immunostained with α-FLAG Ab (upper panel) and
counterstained with DAPI (lower panel). (B) Subcellular localization of acetylation sites
mutants were analyzed by immunostaining; cells expressing different Lys site-specific
APE1mutants were stained with α-FLAG Ab, α-Lamin B Ab and counterstained with
DAPI (C) Western blot analysis of soluble nuclear and chromatin extracts for FLAGtagged WT and mutant APE1 levels in cells ectopically expressing these proteins with αFLAG; α-APE1 and α- Histone H3 and α-msin3a as a control. (D & E) Schematic
overview of the experiment. APE1 was down regulated in HEK293 cells using APE1
specific siRNA, and after 48 hours cells were transfected with expression plasmids
containing WT or K27Q or H309N APE1. Immunofluorescence (IF) assay was performed
using α-FLAG and α-AcAPE1 antibody to check co-localization. At least 50 FLAG
positive cells were counted for co-localization. (E) Proximity Ligation assay (PLA) was
performed using α-FLAG and α-AcAPE1 to examine the acetylation of WT, K27Q and
H309N mutant APE1 in cells. At least 50 cells were counted and percentage of PLA
signal is plotted for each APE1 mutant.
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APE1 is acetylated after binding to AP site damages in the chromatin.
Our confocal and biochemical data clearly indicate that the positive charges of
acetylable Lys residues in APE1, but not their acetylation, are essential for chromatin
association (Fig. 2A & 2C). Still, we consistently observed that AcAPE1 is exclusively
associated with chromatin in both interphase and mitotic cells (Fig.1B & 1D). This led us
to test whether APE1 is acetylated after binding to AP site lesions in chromatin. If
chromatin-binding is necessary for APE1 to be acetylated, then loss of chromatinbinding of K27Q or K31&32Q APE1 mutants (Fig. 2B) is expected to prevent APE1
acetylation at Lys6 residue in cells, and therefore should not be detected by AcAPE1 Ab.
To test this, we downregulated endogenous APE1 levels in HEK293 cells using siRNA.
After downregulating endogenous APE1, we ectopically expressed FLAG-WT or -K27Q
or, -H309N mutants and immunostain with AcAPE1 Ab to compare APE1 acetylation at
Lys6. We reported earlier that mutation of Lys27 residues in recombinant APE1 proteins
does not affect acetylation by p300 at Lys6 in vitro and can be detected by AcAPE1 Ab
in WB analysis (62). Our immunofluorescence (Fig. 2D) and PLA (Fig. 2E) assays show
co-localization of AcAPE1 and FLAG Abs only in FLAG-WT APE1 and H309N APE1, but
not chromatin-binding defective K27Q mutant expressing cells; providing evidence that
chromatin association is necessary for APE1 to be acetylated.
To directly test that acetylation of APE1 occurs after binding to AP site lesions in the
genome in cells, we abrogated binding of APE1 to AP sites by Methoxyamine (MX).
Several earlier studies have established that MX covalently binds to AP sites to form
methoxyamine-bound AP (MX-AP) sites, and competitively inhibits binding of APE1 to
AP sites (91-93). These MX-AP sites are resistant to recognition and repair by the APE1
(91, 92). Thus, we treated the cells with different doses of MX for different time periods,
and found that treatment of MX showed a dose- and time- dependent inhibition of
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chromatin association of endogenous APE1 (Fig. 3A and 3B). This indicates that
observed chromatin association of APE1 was primarily due to AP sites damage binding
on the genome (Fig. 3A and 3B). Interestingly, we observed that MX treatment
completely abrogated APE1 acetylation in a dose and time-dependent manner (Fig. 3A
and 3B). However, MX treatment did not affect the chromatin association of OGG1 (Fig.
3C), a DNA glycosylase which recognizes 8-oxo guanine DNA base damage (61). Thus,
MX treatment does not inhibit chromatin association of other initial enzyme involved in
the BER pathway. To further support the observation that APE1 acetylation occurs after
binding to the AP sites, we induced generation of AP sites in the genome by treatment
alkylating agent Methyl Methane sulphonate (MMS), glucose oxidase (GO), an oxidizing
agent that induces oxidative base damages. These oxidative or alkylated base damages
subsequently generate AP sites after their removal by DNA glycosylases. (94). As
shown in figure Fig. 3D, blocking AP site with MX treatment abrogated acetylation of
APE1 even after induction of AP sites with MMS treatment (Fig. 3D). Moreover, our
biochemical assay revealed that treatment with GO significantly enhanced the levels of
chromatin–bound AcAPE1 levels (Fig. 3E). We also examined the binding or association
of APE1 on the endogenous p21 promoter region in cells via ChIP using AcAPE1 ab
after induction of DNA damage with MMS treatment. A significant enrichment of an
AcAPE1-bound p21 promoter region was observed in MMS treated cells compared to
control (Fig. 3F). Similarly, MX treatment reduced the enrichment of the AcAPE1-bound
promoter region (Fig. 3F). Together, these data suggest that APE1 is acetylated after
binding to AP sites in chromatin in cells.

30

Figure 3: APE1 is acetylated after binding to AP sites in the chromatin. (A) BJhTERT cells were treated with Methoxyamine (MX) (50mM) for indicated time periods. IF
was performed using α-APE1 and α-AcAPE1 and counterstained with DAPI. (B)
HCT116 cells were treated with various doses of MX for 30 mins and IF was performed
using α-APE1 and α-AcAPE1 and counterstained with DAPI. (C) HCT116 cells were
treated with MX 50mM for 30 mins and IF performed using α-OGG1 and counterstained
with DAPI. (D) BJ-hTERT cells pre-treated with or without MX 50mM for 30 mins was
exposed to Methyl Methane Sulfonate (MMS) (2mM) for 1 hour. IF was performed using
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α-APE1 and α-AcAPE1 and counterstained with DAPI. Confocal microscopy was used to
visualize the AcAPE1 level in control and MMS or MX or both treated cells. (E)
Chromatin Immunoprecipitation (ChIP) with α-OGG1 antibody followed by Western
blotting (ChIP-on-Western) was performed, to examine the association of AcAPE1 and
Ligase III on chromatin after induction of DNA damage with glucose oxidase (GO). (F)
Association of AcAPE1 on endogenous p21 promoter was examined by promoter
directed ChIP using α-AcAPE1 in control or MMS or MX treated cells.
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Acetylation of APE1 enhances its AP endonuclease activity or catalytic efficiency.
We investigated directly whether acetylation affects the AP-endonuclease activity of
APE1 in vitro. Purified WT APE1 was incubated with p300 HAT domain either in the
presence or absence of AcetylCoA and then acetylation of APE1 was confirmed by
Western analysis using our AcAPE1 specific Ab (Fig. 4A). We found that acetylation of
APE1 increased its AP-endonuclease activity in a dose-dependent manner (Fig. 4B).
We determined the steady-state parameters for both recombinant unmodified APE1 and
AcAPE1 during the linear increase period (up to 3 min, of product formation (Fig. 4C
and 4D). Enzyme Kinetic analysis showed that both APE1 and AcAPE1 have
comparable binding affinity (Km) for the substrate AP sites (Fig. 4E). However,
acetylation enhanced catalytic (Kcat) turnover of APE1 in vitro (Fig. 4E). Thus AcAPE1
has a higher (~-3fold) kcat/km ratio, i.e increased catalytic efficiency.
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Figure 4: Acetylation of APE1 enhances its AP endonuclease activity. (A) Rec.
APE1 was incubated with p300 HAT domain either in the presence or absence of
AcetylCoA and Western blot analysis was performed with α-APE1 and α-AcAPE1 Abs to
confirm acetylation of APE1. (B) Incision of the THF (reduced AP-site)-containing 43mer duplex oligonucleotide (Substrate: S) by APE1 and in vitro acetylated APE1; the
cleaved product (P). (C, D) The kinetic parameters Km and kcat were calculated by
incubating 33 pM enzymes at 37°C for 3 min with substrates at various concentrations
(0-160 nM). The enzyme kinetics data were fitted into nonlinear least-squares regression
to obtain Vmax and Km with the Michaelis–Menten equation using Sigma plot software.
(E) Comparison of kinetic parameter between APE1 and AcAPE1.
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APE1 acetylation enhances its interaction with downstream BER proteins and
stability on chromatin.
In cells, total (complete) repair of AP sites is not only dependent on AP-endonuclease
activity of APE1 but also its interaction and coordinated recruitment of downstream BER
proteins such as DNA polymerase beta (polß) and XRCC-1/DNA ligase III (95-97). APE1
has been shown to incise the AP-site and remains tightly bound to the cleaved AP site
product and serve as a mediator for the next step in the BER pathway. Thus when
bound to the cleaved AP site, APE1 physically interacts with polß and significantly
stimulates its dRP-lyase activity (90, 97). Moreover, interaction of APE1 with XRCC1
was shown (98). Consistent with this idea, we observed that AcAPE1 co-localizes with
Ligase III in chromatin (Fig. 5A). Furthermore, we found that treatment with TSA which
enhances APE1 acetylation levels (57) increased association of XRCC1 with WT-APE1
but not with non-acetylable K6R/K7R mutant (Fig. 5B). This indicates that acetylation of
APE1 enhances its interaction with XRCC1( (99). Interestingly, we found that preextraction of loosely associated proteins with 0.5% Triton-X-100 and salt prior to fixation
significantly decreased staining for non-modified APE1 but did not have any effect on
AcAPE1 staining in the nucleus (Fig. 5C). This suggests that APE1 is more stable on
chromatin when it is acetylated.
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Figure 5: APE1 acetylation enhances its stability on chromatin and interaction
with downstream BER proteins. (A) Co-localization of Ligase III and AcAPE1 in A549
cells. Cells were immunostained with α-ligase III and α-AcAPE1 Abs. (B) WT or K5R
APE1 overexpressing HEK293 cells were treated with or without TSA/NAM for 6 hrs and
nuclear extract was immonoprecipitated using α-FLAG Ab and immunoblotted with αXRCC1 and α-FLAG Abs. (C) A549 cells fixed with paraformaldehyde before (upper
panel) or after treatment with Triton X-100 (0.5%) (middle panel) or Triton X-100 plus
salt (100 mM KCl, lower 203 panel) and immunostained with α- APE1, α-AcAPE1 Abs
and counterstained with DAPI. (D) Acetylation of APE1 induces a conformational change
in APE1. Distinct intrinsic fluorescence emission spectra of APE1 and AcAPE1 at 280
nm.
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Acetylation induces a conformational change in APE1.
So far, our data suggest that upon binding to the AP site in the chromatin, APE1 is
acetylated and AcAPE1 has higher catalytic efficiency. We tested the possibility that
acetylation-mediated neutralization of positive charges of Lys residues in the N-terminal
could induce a conformational change in APE1, and that this may increase its catalytic
efficiency. We compared the UV fluorescence of both unmodified and AcAPE1. WT
APE1 contains seven tryptophan (Trp) and eleven Tyrosine (Tyr) residues, all of which
are located in its globular core domain (aa 42-318) (100). Trp residues that are exposed
to water have maximal fluorescence at a wavelength of about 340-350 nm, whereas
totally buried residues fluoresce at about 330 nm (101). Excitation at 280 nm (for both
Tyr and Trp) showed a typical Trp emission spectrum of WT APE1 with max 329 nm.
However, AcAPE1 showed a red shift (max 339 nm), indicating a more solvent exposed
environment for the Trp residues when APE1 is acetylated. (Fig. 5D). These data
together suggest that acetylation of APE1 induces a conformation change in APE1.
Absence of acetylation in APE1 cells accumulates AP-sites in the genome.
The observation that APE1 acetylation enhances its endonuclease activity raises the
possibility that in the absence of acetylable Lys residues, cells will accumulate AP sites
in the genome. We quantitated AP sites in the genome of cells expressing WTAPE1 and
non-acetylable APE1 mutants by using an aldehyde-reacting probe (ARP). We used
HEK293TAPE1siRNA cells stably expressing APE1-siRNA under a Dox-inducible promoter,
as described earlier (57, 67). We treated the cells with Dox (1 ug/ml) to deplete
endogenous APE1 and then ectopically expressed FLAG-tagged WT-APE1, or its
mutants lacking the acetylation sites. AP sites in the genome were quantitated using
aldehyde reactive probe (ARP) (94, 102). As expected, we observed that depleting
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endogenous APE1 with Dox significantly increased AP sites in the genome compared to
control (Fig. 6A). This effect can be partially rescued by ectopic expression of WTAPE1, but not with its non-acetylable K5R or chromatin-binding defective K5Q or
 mutants (Fig 6A). We also treated these cells with glucose oxidase to induce
oxidative damages, which in turn produced AP sites in the genome. As shown in Fig.
6B, treatment with glucose oxidase significantly enhanced AP sites in the genome of
APE1 downregulated cells. These can be reduced by ectopic expression of WT APE1,
but not with either non-acetylable K5R or K5Q mutant. Together, these data indicate that
the presence of acetylable Lys residues and acetylation of these residues in APE1 play
a crucial role in endogenous DNA damage or AP site repair in cells.
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Figure 6: APE1 acetylation is essential for cell survival and/or cell proliferation
and absence of APE1 acetylation sensitizes cells to DNA damaging agent. (A, B)
EndogenousAPE1 was downregulated in HEK293TAPE1siRNA cells using doxycycline
(Dox) treatment. FLAG tagged WT APE1 or acetylation defective (mutations of
Lys6,7,27,31&32 to non-acetylable arginine (K5R) or glutamine (K5Q)) or N-terminal
deletion (NΔ33) mutants were further overexpressed in these cells. Cells were treated
with or without Glucose oxidase (100ng/ml for 30 mins) and AP sites were measured
using ARP kit. Bar diagram representing number of AP site/10^5 bp in presence of
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different APE1 mutants compared to vector control. Error bars indicate mean ±SD (n=3).
(C) HEK293TAPE1siRNA cells were treated with/without DOX and WT, K5R and K5Q
mutant APE1 were ectopically expressed. Cells were treated with or without glucose
oxidase (100 ng/ml for 30 min) and colony formation assay was performed. Bar diagram
representing number of colony formed in presence of different APE1 mutants compared
to vector control. Error bars indicate mean ±SD (n=3). (D, E) HCT116 cells constitutively
expressing APE1 shRNA; HCT116APE1shRNA, were transfected with FLAG tagged WT
APE1 or acetylation defective (mutations of Lys6,7,27,31&32 to non-acetylable arginine
(K5R) or glutamine (K5Q)) APE1 mutants. Western blot analysis was performed to
examine APE1 levels using α-APE1 Ab. α-HSC70 was used as loading control.
(E)Damage sensitivity was measured in HCT116APE1shRNA cells ectopically
expressing different APE1 mutants. Cells were treated with increasing dose of MMS for
1hrs and colony formation assay was performed.
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APE1 acetylation plays a critical role in cell survival and/or proliferation in
response to genotoxic stress
We examined the role of APE1 acetylation in cell survival and/or proliferation, measuring
cell survival by clonogenic survival assay. As expected, we observed that depleting
endogenous APE1 with Dox significantly decreased the number of viable colonies
compared to control (Fig. 6C). This effect can be rescued by ectopic expression of WT
APE1, but not with non-acetylable K5R or K5Q mutants (Fig. 6C). We further examined
the role of APE1 acetylation in cell survival or proliferation after induction of DNA
damage. Treatment with GO decreased the number of viable colonies which can be
rescued by ectopic expression of WT APE1, but not with its non-acetylable mutants (Fig.
6C). Furthermore, we transfected HCT116 cells that stably expressing APE1 shRNA
(HCT116APE1shRNA) with FLAG-tagged WT, and noncaetylable K5R or K5Q mutants.
Western blot analysis showed that the expression levels of WT APE1 was significantly
low compared to non-acetyalable K5R , K5Q and endogenous APE1 level in control
HCT116 cells (Fig. 6D). We found that treatment of alkylating agent MMS sensitized the
HCT116APEshRNA cells in –a dose-dependent manner (Fig. 6E). This effect can be
partially rescued by ectopic expression of WT APE1, but not with non-acetylable K5R or
K5Q mutant protein which is present in higher levels in cells (Fig. 6E and 6D). These
data indicate that APE1 acetylation plays a role in cell survival and/or proliferation and
that the absence of APE1 acetylation in cells sensitizes them to DNA damaging agents.

2.4 Discussion
Unrepaired AP sites in the genome can inhibit transcription, and block DNA replication
(9, 75, 103). Thus, the presence of an efficient repair mechanism is essential for cell
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survival and/or proliferation. We reported earlier that multiple Lys residues in the
intrinsically disordered N-terminal domain of APE1 are modified by acetylation in cells
(56, 62). Further, using conditional APE1-nullizygous mouse embryo fibroblasts (MEF),
we showed that both the DNA repair function and acetylable Lys6 and Lys7 residues of
APE1 are essential for cell survival (72). Moreover, a recent study showed that the
absence of acetylation at Lys 6 and Lys7 sites in APE1 or its DNA repair function results
in telomere fusion and mitotic defects (73). Given the key role of APE1 in the repair of
AP sites which inhibits transcription and replication (5, 75, 103), the essential role of
DNA repair function of APE1 in cell survival is not surprising (6, 24, 72, 78). However,
what was unexpected was the critical importance of APE1’s acetylation for cell survival
and proliferation (72). In this study, we demonstrated that acetylation of APE1 plays a
crucial role during the repair process of AP sites in the genome in cells via the BER
pathway. Our study documents that APE1 is acetylated after binding to AP sites in the
chromatin and acetylation not only improves the catalytic efficiency of APE1 but also
may facilitate coordination and recruitment of the downstream enzyme in the BER
pathway. Thus, acetylation of APE1 is likely to be an integral part of the APE1dependent BER pathway for maintaining DNA integrity.
Although the N-terminal domain (1-61 aa) of APE1 is dispensable for its in vitro DNA
repair activity (104, 105), this study unraveled the novel regulatory role of acetylation of
multiple Lys residues in this domain, in AP site repair both in vitro and in cells. Our study
provides direct evidence that APE1 after acetylation enhances its AP-endonuclease
activity in vitro. We also have provided evidence that the absence of acetylation in APE1
cells accumulates AP sites in the genome and becomes sensitive to DNA damaging
agents. Several lines of evidence support that APE1 is acetylated at Lys6 residues after
binding to AP sites in the chromatin. First, AcAPE1 is exclusively present on chromatin
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throughout cell cycles in all types of cells including primary, transformed, and tumor.
Second, the inhibition of binding of APE1 to AP sites by MX treatment abrogates APE1
acetylation in a dose and time-dependent manner. Third, APE1 mutants that are
proficient in acetylation but cannot bind to chromatin cannot be acetylated in cells.
Finally, induction of AP sites in the genome by MMS treatment enhanced APE1
acetylation and occupancy of AcAPE1 on chromatin.
Stimulation of the AP-endonuclease activity of APE1 due to acetylation suggests
multiple possible mechanisms. An acetylation-induced conformational change in APE1
could either increase its affinity for the substrate AP site in DNA; or, it could facilitate AP
site cleavage or decrease APE1’s affinity for the product (cleaved AP-site), thus
increasing its turnover. Our data, showing that both WT and AcAPE1 have comparable
affinity Km for the substrate AP sites but different Kcat, suggest that an acetylationinduced conformational change in APE1 could either facilitates AP site cleavage or
increase the dissociation of APE1 from the product (cleaved AP-site) thus increasing its
turnover. However, APE1 has been shown to incise the AP-site, remain tightly bound to
the cleaved AP site product, and serve as a mediator for the next step in the BER
pathway (97). Efficient complete (total) repair of the AP site is not only dependent on
APE1 endonuclease activity, but also on the coordination and interaction of APE1 with
downstream BER proteins (32, 95, 97, 98). Thus, when bound to the cleaved AP site,
APE1 physically interacts with DNA polß and significantly stimulates its dRP-lyase
activity (90, 97). Interaction of APE1 with XRCC1 was also shown (98). Consistent with
this idea, we observed that AcAPE1 interacts with Ligase III in chromatin and that
acetylation of APE1 enhances its interaction with XRCC1. Thus APE1 after acetylation
not only facilitates AP sites cleavage in the chromatin but may also enhance
coordination of total AP site repair in cells.
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In the absence of any structural information about full-length APE1 or its binary complex
with AP site containing oligo, it is not easy to establish if these acetylable Lys residues
directly interact with AP sites containing DNA or C-terminal active site domain. Our data
shows that the positive charges of the acetylable Lys residues are important for its
nuclear retention and/or chromatin binding and neutralization of positive charges of
acetylable Lys residues reduced its chromatin association. It is likely that basic Lys
residues in the N-terminal domain of APE1 may dynamically interact with DNA or with
acidic residues in interacting partner proteins including nuclear importin complexes for
nuclear localization or nucleosome remodeling complexes that facilitate binding access
of APE1 to AP sites in nucleosomes in the context of chromatin in cells. Consistent with
this, earlier studies by our group and others have shown that the APE1 N-terminal 33 aa
is required for interaction with many interacting partners, and neutralization of positive
charges in APE1 affects their interaction (67, 68). Intrinsically unstructured regions and
electrostatic forces are known to be generally important for intramolecular interactions.
Similar to our observation, a study has shown that NEIL1, a DNA glycosylase involved in
oxidative damage repair, has an intrinsically disordered C-terminal domain (311-389 aa)
that is involved in intramolecular interaction with a negative charge core domain (106).
This domain was also shown to be essential for interaction of NEIL1 with many binding
partners (107).
We propose a model (Fig. 7) by which APE1 acetylation regulate the AP site repair in
cells. When APE1 locates AP sites in the genome, the first stable APE1-AP DNA
complex is formed. Subsequent recruitment of p300 to the damage sites acetylates
APE1. Acetylation-mediated neutralization of multiple positive charges at multiple Lys
residues in the N-terminal may disrupt the intramolecular interaction, which induce a
conformational change in the catalytically active domain in APE1 which facilitates AP
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sites cleavage in DNA. Consistent with this, one study has shown that neutralization of
the positive charges of the Lys residues in the N-terminal domain or deletion of the Nterminal domain of APE1 significantly enhanced the AP-endonuclease activity of APE1
in vitro (68). Moreover, our current data show a similar change (red shift) in Trp emission
in APE1 after its acetylation. Since, acetylation of APE1 improves the turnover rate of
APE1 and also enhances the interaction with XRCC1, it appears that the acetylation of
APE1 has evolved not only to improve the catalytic efficiency but also to facilitate
coordination and recruitment of the downstream enzyme in the BER pathway.

We

hypothesize that, after AP site cleavage, AcAPE1 remains bound to the cleaved AP-sites
and subsequent recruitment of polß displace APE1 from the 5`-deoxyribose phosphate
of cleaved AP site (but no from DNA) which is enhanced when APE1 is acetylated. Thus
acetylation-induced conformation change in APE1 not only enhances its cleavage
activity, and at the same time may facilitate co-ordination with the next BER proteins.
Such a mechanism might also help to explain why AcAPE1 is associated with ligase III
and the XRCC1 complex, and why acetylation stimulates their interaction in cells.
Finally, recruitment of the histone deacetylase SIRT1 (108, 109), deacetylates AcAPE1,
and that displaces APE1 from the DNA. Consistent with this finding, an earlier study
showed SIRT1 can deacetylate APE1 in vitro and in cells and that it regulates cellular
BER (109).
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Figure 7: Schematic model for regulation of AP sites repair in cells by acetylation
of APE1 via BER pathway.
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Our novel discovery highlights that the conserved acetylable Lys residues in unique Nterminal domain (present only in mammalian APE) of APE1, and that their modifications
are evolved to finely regulate and co-ordinate the efficient repair of the AP site in
mammalian cells. Thus mutation of either catalytically active sites or acetylation sites in
the N-terminal would have profound cellular consequences such as growth arrest and/or
cell death, Consistent with this hypothesis, we showed earlier that both the DNA repair
function and acetylable Lys6 and Lys7 residues of APE1 are essential for cell survival
(72). Moreover, a recent study by Madlener and colleagues showed that APE1 is
essential in maintaining telomere length, presumably through maintenance of DNA
integrity in that region (73). They found that both the DNA repair function active H309 or
N212 sites and acetylable Lys 6/7 sites in APE1 are essential for maintaining telomere
length (73). We believe that mitotic telomeres might be prone to oxidative damages and
generate AP sites and the absence of AcAPE1-mediated AP site repair leads to
accumulate DNA breaks in this region, this will lead to telomere fusion and mitotic
defects. Indeed, they found that absence of acetylation of APE1 or its DNA repair
function leads to mitotic defects. Of note, our confocal IF data demonstrate the presence
of AcAPE1 on condensed chromatin during all stages of mitosis. This indicates that AP
sites are also generated in the genome during mitosis; AcAPE1-mediated BER may be
also operative. Further studies are necessary to establish this.
Nonetheless, our findings demonstrate that APE1 acetylation is an integral part
of the BER pathway in cells for maintaining genomic stability and also provide the
mechanism by which APE1 acetylation plays a key role in the repair of AP sites or
oxidative DNA damages. Our study also implicates that dysregulation of APE1
acetylation/deacetylation cycle may lead to genomic instability and cause many human
diseases, including cancer, premature aging.

47

CHAPTER 3

Endogenous oxidative base damage and base excision repair
regulate the formation of G-quadruplex structures in the genome

The materials presented in this chapter is submitted to a peer-reviewed journal as of
May 2019.
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3.1 Introduction
G-quadruplexes (G4) are non-canonical tetrahelical nucleic acid structures that arise
from the self-stacking of two or more guanine quartets, a planar array of four guanine
residues coordinated through Hoogsteen hydrogen bonding (110, 111). Numerous in
vitro biochemical and structural analyses have established that both DNA and RNA
sequences having a specific consensus motif (G ≥3 N1-7G≥3 N1-7G ≥3 N1-7G≥3 ) can form G4
structures (112). Formation of G4 DNA structures in the genome have emerged as an
epigenetic mechanism for regulating transcription, replication, translation and telomere
maintenance (113). Deregulation of formation (folding) or unfolding of G4 has been
implicated in transcriptional dysregulation, telomere defects, replication stress, genomic
instability and many human diseases including cancer and neurodegeneration (114118). A breakthrough in establishing the regulatory role of G4 in vivo came from the
recent genome-wide mapping of G4s in human cells using high-throughput chromatin
immunoprecipitation-sequencing (ChIP-Seq) with a specific antibody directed against G4
structure (113, 119, 120). Mapping revealed that G4 structures are non-randomly
located and overrepresented in areas of key regulatory regions like gene promoters, 5’
and 3’ untranslated regions and telomeric regions, suggesting a positive selective
pressure for retention of these motifs at specific sites in the genome for regulating
multiple biological processes. In vitro, many G4 DNA structures once formed are
thermodynamically more stable than double-stranded DNA (121). However, for biological
functions, their formation (folding), stabilization, and unfolding must be regulated. While
several proteins (DNA or RNA helicases) that bind to and resolve G4 structures have
been characterized (122), the mechanism(s) underlying spatiotemporal formation and
stabilization of G4 structures in the genome are largely unknown.
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Guanine (G) residues in potential G-quadruplex-forming sequences (PQS) have the
lowest oxidation potential and are likely to be susceptible to the formation of 8oxoguanine (8-oxoG), the most prevalent endogenous oxidative base damage in the
genome (123, 124). 8-oxoguanine DNA glycosylase (OGG1) initiates the repair of 8oxoG via evolutionary conserved DNA Base Excision Repair (BER) pathway by
removing the oxidized base and generating an Apurinic/apyrimidinic (AP/abasic) site
(125, 126). Human AP-endonuclease 1(APE1) is then recruited to the AP sites for repair
through the BER pathway (77). APE1, a key enzyme in the BER pathway, is a multifaceted protein involved in telomere maintenance, transcription regulation and antibody
genesis, highlighting role of BER beyond its genome maintenance function (34, 72, 73,
76, 127). However, the molecular and functional connection of the endogenous DNA
damage and APE1 with the G4 structures remains largely unclear. Here, we conduct an
unbiased genome-wide mapping of G4 structures, along with oxidative base damage,
AP sites, and binding of OGG1 and APE1 proteins, and provide the first direct evidence
that occurrence of endogenous base damage is non-random and is predominant in PQS
sequences. Visualizing G4 dynamics in cells using high-resolution microscopy, we
demonstrate that oxidative base or AP site damages and the associated repair
complexes play a critical role in the spatiotemporal regulation of G4 structures. Loss of
either repair function or acetylation of APE1 results in the abrogation of G4 structures
and deregulation of gene expression. Using in vitro biophysical and cell biological
assays, we provide evidence that AP site damage and binding of APE1 to PQS
promotes G4 formation and facilitates transcription factors loading to regulate gene
expression. Overall, our study comprehensively elucidates the role of endogenous base
damage and the BER pathway in controlling the formation of G4 structures in the
genome to regulate transcription and other biological processes.
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3.2 Materials and methods
Cell culture, plasmids, reagents: The human lung epithelial adenocarcinoma cell line
A549 (ATCC # CCL-185), human lung fibroblast cells IMR-90 (ATCC #CCL-186), human
embryonic kidney HEK-293T (ATCC # CRL-3216), human pancreatic ductal
adenocarcinoma PANC-1 (ATCC #CRL-1469) and wild type and Ogg1-null mouse
embryonic fibroblast (MEF) cells (kindly provided by Dr. Istvan Boldogh, University of
Texas Medical Branch, Galveston), were maintained in Dulbecco's modified Eagle's
medium (DMEM) with high glucose (Thermo Fisher Scientific). Human Colon cancer
HCT116 (ATCC #CCL-247) was grown in McCoy’s 5A medium (Thermo Fisher
Scientific). All media were supplemented with 10% fetal calf serum (FCS; Sigma) and an
antibiotic mixture of 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco-BRL). All cell
lines were authenticated by STR DNA profiling by Genetica DNA laboratories,
Burlington, NC. For APE1 knockdown studies, HCT116 cells stably expressing APE1shRNA or control shRNA (83) were maintained in 10% FBS supplemented MaCoyx 5A
medium with 1ug/ml puroMycin. Transient APE1 knockdown was achieved using
APE1siRNA (sigma) transfected to indicated cell lines for 72 hours. To generate the
Doxycycline-inducible APE1 shRNA or control shRNA expressing stable A549, HCT116,
HEK-293T, PANC-1 cells, three different SMARTvector doxycycline inducible Human
APE1-shRNA lentiviral constructs (shRNA #V3IHSHEG_5634292/6377584/7228555
named as 1/2/3 respectively; Dharmacon) or non-targeting control shRNA construct with
GFP were transfected individually into HEK-293T with packaging plasmids using xtremeGENE HP DNA transfection reagent (Sigma) to generate lentiviral supernatants
and individual supernatants were transduced into above-mentioned cell lines and
selected

with 1 ug/ml puromycin. All doxycycline-inducible APE1-shRNA stable cell

lines were maintained in respective media supplemented with tetracycline free 10%
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Fetal Bovine Serum (Atlanta biologicals). For rescue experiments, HEK-293T APE1shRNA /
HCTT16APE1shRNA cells were treated with Doxycycline (2 ug/ mL) for 3 days to knockdown
the APE1 levels and then cells were transfected with FLAG-tagged WT APE1, or
acetylation defective K5R (Lysine 6,7,27,31,32 to arginine ) or repair defective H309A or
redox defective C65,99S mutants of APE1 using Lipofectamine 3000 (Invitrogen) in
serum-free Opti-MEM media (Thermo Fisher Scientific) and cell were fixed after 24 hrs
of transfection. Expression plasmid Adenovirus EIA12S (86) were transfected using
Lipofectamine 3000 (Invitrogen) and harvested after 48 hrs. Methoxyamine, Glucose
oxidase, hydrogen peroxide, Methyl Methanesulfonate, ActinoMycin D, Aldehyde
Reactive Probe (ARP) were obtained from Sigma.
Immunofluorescence analysis: Cells were cultured on coverslips, fixed for 30 min in
4% formaldehyde (Sigma) and then permeabilized and blocked in PBS with 0.5% Triton
X-100 (Sigma), 10 % goat serum (Thermo-Fisher #50062Z), glycine, sodium azide for 1
hour at room temperature. Cells were then incubated with primary antibodies in blocking
buffer overnight at 4°C followed by 1 h further incubation with the corresponding
secondary antibodies Alexa Fluor 488 anti-mouse IgG (Life Technologies, 1:500) or
Alexa Fluor 594 anti-rabbit IgG (Life Technologies; 1:500) at room temperature (RT) in
blocking buffer. Cells were then washed in PBS and mounted using mounting media with
DAPI (Vector Laboratories –Item # VV- 93952-27) for confocal microscopy and superresolution structured illumination microscopy (SIM). For G quadruplex staining, after
formaldehyde fixation, cells were permeabilized in PBS containing 0.5% Tween 20 for 20
mins at 37° incubator, then treated with 20 µg/ 500 µL RNase A (Invitrogen) and
subsequently blocked and processed as mentioned previously (128). For DNase
experiments; cells were fixed in 4% PFA in PBS for 30 min at room temperature,
permeabilized with 0.2% Triton X-100 in PBS for 1 min and washed in PBS. They were
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then incubated for 2 hrs at 37 °C in 40 mM Tris-Cl (pH 8), 5 mM CaCl2, 2 mM MgCl2, 100
ug/ml BSA alone or including 0.06 U/ul of DNase I (RQ1 DNase, Promega), washed in
PBS and then stained with antibodies. Three- dimensional (3D) SIM images were
collected with an ELYRA PS.1 illumination system (Carl Zeiss). All images were
analyzed using the ImageJ software. The Pearson correlation coefficients were
calculated using the JACoP co-localization analysis module of the ImageJ software. To
quantify the level of co-localization, a threshold was first established using the inbuilt
JACoP threshold optimizer followed by calculation of correlation coefficients. Primary
antibodies used for immunofluorescence studies were mouse monoclonal anti-APE1
(1:100; Novus Biologicals; # NB100-116), anti-AcAPE1 (1:50; (55)), Anti-AcOGG1 (1:50;
(61)),Anti-G4-1H6 ( 1:50; Millipore), Anti-ECD (1:100;(129)) Anti-H3K27 acetylated
histone (1:100; Millipore; #05-1334), Anti- H3K4Me3 (1:100; Millipore) and anti-c-Jun
(1:100;Abcam).
Chromatin Immunoprecipitation (ChIP) Analysis: Cells were plated in 150 mm
culture dish for overnight. Next day, cells were subjected to 1% formaldehyde
crosslinking (15 min incubation at room temperature) in PBS. The crosslinked cells were
washed thrice in PBS and scraped off the cells in PBS (containing PI), pelleted at 1000
rpm (10 min, 4 ºC). The pelleted cells were lysed in SDS lysis buffer (1% SDS, 10 mM
EDTA, 50 mM Tris-HCl pH 8), incubated on ice for 10 min and subjected to sonication
(Misonix sonicator 3000 ) on ice by setting the pulse at 4 min for 4 times with 15 seconds
interval in between, followed by centrifugation (14000 rpm, 15 min, 4ºC) to collect the
sonicated clear sheared chromatin lysate. IP was done in this lysate with corresponding
antibody (5 µg; control IgG included in a separate IP) in a total volume of 2 ml (diluted
1:10 with ChIP dilution buffer: 0.01% SDS, 1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM
Tris-HCl pH 8.1, 167 mM NaCl) overnight (4ºC) with constant shaking. Next day, 25 ul
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dynabeads were added to each reaction and incubated in 4°C shaker for 2 hours. The
IPs were washed sequentially with low salt immune complex wash buffer (0.1% SDS,
1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8, 150 mM NaCl), high salt immune
complex wash buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8,
500 mM NaCl), LiCl immune complex Wash Buffer (0.25 M LiCl, 1% NP40, 1% Nadeoxycholate, 1 mM EDTA, 10 mM Tris-HCl pH 8) and TE Buffer (10 mM Tris-HCl, 1
mM EDTA pH 8). The protein-DNA complexes were eluted in ChIP elution buffer (1%
SDS, 0.1 M NaHCO3), de-crosslinked in 200 mM NaCl for overnight at 65ºC. ChIP DNA
was purified by RNAse treatment, proteinase K digestion, phenol-chloroform extraction,
and precipitation by 100% ethanol precipitation using a standard protocol. The ChIPpurified DNA was finally dissolved in ultrapure water. For damage AP-seq, 1 mM biotinconjugated ARP was fed to cells for 3 hours, and direct streptavidin pull-down was
performed on sonicated lysate followed by other steps as described above. The ChIP
and 1% input DNA were subjected to SYBR GREEN-based Real-Time PCR (7500 RealTime PCR System; Applied Biosystems) with primers (Table below). Data were
represented

as

%

input

calculation

((2^(adjusted

input-ChIP

CT))*100).Immunoprecipitation (IP) was performed with antibodies: rabbit α-APE1, rabbit
α-AcAPE1 (55), rabbit α-AcOGG1 (61), mouse α-BG4 (Absolute biology), mouse α -MAZ
(Santa Cruz), or control IgG (Santa Cruz) and Dynabeads Protein A/G Magnetic beads
(Millipore, # 16-661).
Primer name

Forward sequence

Reverse sequence

KRAS G4

GTACGCCCGTCTGAAGAAGA

GAGCACACCGATGAGTTCGG

Neg G4

CTCCGACTCTCAGGCTCAAG

CAGCACTTTGGGAGGCTTAG

MYC

CAGGCAGACACATCTCAGGG CGTATACTTGGAGAGCGCGT
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P21

CAGGCTGTGGCTCTGATTGG

TTCAGAGTAACAGGCTAAGG

ChIP-Sequencing analysis: The ChIP-purified DNA was provided to University of
Nebraska Epigenomics Core. ChIP DNA was quantified by Qubit (Invitrogen), and then
New England Biolabs NEB Next Ultra II DNA Library Prep Kit for Illumina was used to
create library. High-throughput sequencing was conducted at the UNMC Sequencing
Core, using an Illumina HiSeq 2500 Genome Analyzer. Adaptor sequences and low
quality (Phred score < 20) ends were trimmed from sequences using Trim Galore
software

package

(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/).

Resulting fastq files were aligned to the human genome (GRCh37/hg19) using the
sequence aligner Bowtie2 (version 2.2.3) (130). The software package Picard routine
Mark Duplicates (http://broadinstitute.github.io/picard/) was used to remove sequence
duplications. 20 million reads per sample were then analyzed using both MACS2 peak
caller (131) software (version 2.1.1) and Homer. Enrichment of DNA sequence with
specific Ab over IgG (p<.001; fold change >2; reads>15 contributing to each peaks) was
considered significant. Both analysis programs scored read-density across genomic
DNA and define peak regions where a bimodal enrichment of reads has occurred. All
bigWig

files

were

generated

using

the

deeptools

bamCoverage

routine

(https://deeptools.readthedocs.io/en/develop/) were uploaded and displayed on the
UCSC Genome browser with a cut off at 5 reads. SeqMonk was used to analyze
distribution with respect to TSS. Graph-pad Prism was used to calculate correlation
coefficient between BG4 and APE1 or AcAPE1 promoter binding peaks.
Western blotting: Western blotting was performed using standard methods, as
described previously ((56)). Primary antibodies used in the study includes mouse
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monoclonal anti-APE1 (1:5000; Novus Biologicals; # NB100-116), mouse anti-HSC70
(1:10000; Santa cruz), Anti-ECD (1:1000;(129)) , beta-actin (1:1000).
RNA Seq and quantitative RT PCR: Doxycycline inducible A549APE1shRNA cells were
treated with Doxycycline (2 ug/ mL) in triplicate for 3 days to knockdown the APE1
levels. Total RNA was purified using a Qiagen kit (#74104). Total RNA was subjected to
Illumina Hi-seq. For q RT-PCR, total RNA was isolated from cells using TRIZOL method.
cDNA synthesis of 1 ug of total RNA was performed with the MulV RT kit (Invitrogen)
using random hexamer primers. For quantitative Real-Time PCR (qRT-PCR) analyses,
1/50th of each reaction was used. RT-PCR analysis was performed using SYBR green
(Applied Biosystems) for detection with an Applied Biosystems StepOne Plus system.
Fold change was calculated by specific gene 2^-(target-reference)/GAPDH

2^-(target-reference)

. The

following gene-specific primers were used,
Primer
name

Forward sequence

Reverse sequence

KRAS

TCTTGCCTCCCTACCTTCCACAT CTGTCAGATTCTCTTGAGCCCTG

GAPDH

TGGGCTACACTGGAGCACCAG

GGGTGTCGCTGTTGAAGTCA

Site-directed mutagenesis and Luciferase assay: The Del4 luciferase reporter plasmid,
harboring the 22-mer c-MYC G4 forming sequence in the P1 promoter upstream of the
luciferase reporter (Addgene plasmid # 16604) was mutated using the QuickChange
Site-directed Mutagenesis kit (Agilent Technologies, CA, USA) to generate a mutated
G4-forming sequence.


Del4: 5′-G4AG3TG4AG3TG4-3′
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G12A: 5′-G4AG3TGAG2AG3TG4-3′ (Kindly provided by Dr. Jyoti Dash; Indian
Association for the cultivation of science; India,(132))



G18A: 5′-G4AG3TG4AGAGTG4-3′

pRL -TK renilla luciferase (Addgene plasmid #E2241) control reporter vector was used
for measuring transfection efficiency and as a non-G4 sequence control. 1 ug Del4
plasmid with 100 ng of pRL -TK plasmid was transfected to cells plated on a six-well
plate using Lipofectamine 3000 as per manufacture's protocol. After 48 hours cells were
lysed and luciferase assay was performed using Dual-luciferase reporter assay
(Promega) according to manufacturer protocol in Glow-max (Promega) system.
Preparation of G4 DNA-containing templates: Synthetic single-stranded DNA
templates and complimentary strands were purchased from Midland-certified reagents.
The oligomer sequences are listed in Table. Synthetic double-stranded DNA templates
were generated by incubating 10 uM of each strand in a final volume of 100 μL of
annealing buffer for 5 min at 95°C, followed by slow cooling down from 95 °C to 37 °C.
To induce G4 DNA formation, the annealing reaction was carried out in the presence of
100 mM KCl. After the annealing step, samples were stored at −20°C.
Oligo name

Sequence

MYC-AP

(Cy5)ATAAGCTTCCCGGGGTCGACCACGTCTGGGGAGGGTG(abasic)

75

mer GGAGGGTGGGG AAGGTCTAGATCTGGTACCGAATTCT

template
strand
Complimen

TATTCGAAGGGCCCCAGCTGGTGCAGACCCCTCCCACTCCTCCCAC

tary strand

CCCTTCCAGATCTAG ACCATGGCTTAAGA
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CD spectroscopy: Circular Dichroism (CD) spectra were obtained on a JASCO J-810
spectropolarimeter, equipped with a thermostated cell holder, with 1 μM oligonucleotides
solutions in 50 mM HEPES pH 7.5, 10 mM NaCl, 10 mM MgCl2, 5% glycerol, 1 mM
DTT, 0.1 mg/ml BSA. The spectra were recorded in 10 mm quartz cuvette at 20 °C.
Scans were performed at 20 °C over a wavelength range of 210-330 nm with a response
time of 0.5 s, 1 nm pitch and 1 nm bandwidth. Blank spectra of samples containing
buffer were subtracted from DNA samples. The spectra are reported as ellipticity (mdeg)
versus wavelength (nm). Each spectrum was recorded five times, smoothed and
subtracted to the baseline.
EMSA: A 75-mer oligonucleotide containing the G4-forming sequence and an AP site
analog, tetrahydrofuran at position 12 of the c-Myc NHEIII1 was labeled at the 5' end
with cy5 and annealed to a complementary strand as described above. This substrate
(30 nM) was mixed at with increasing dose of APE1 (6.4, 64 and 640 ng) at room
temperature in electrophoretic mobility shift assay buffer containing 50 mM HEPES pH
7.5, 10 mM NaCl, 10 mM MgCl2, 5% glycerol, 1 mM DTT, 1 mM EDTA, 0.1 mg/ml BSA.
One ug of poly-deoxy-inosinic-deoxy-cytidylic acid (Poly[dI-dC]) was used in each
reaction as non-specific competitor. Aliquots of the binding mixtures were chilled in ice
after incubation for 10 min at room temperature. The protein-bound DNA was separated
from the free substrate by electrophoresis on a 10% non-denaturing polyacrylamide gel
at 100 V/cm2 for 60 min.
Fluorescence Recovery After Photobleaching (FRAP): A small region in the nucleus
of a cell was photobleached with three iterations at 100% laser intensity, and
subsequently recovery of fluorescence was monitored 200 times every 20 ms at 1%
laser intensity (25 mW Argon laser, 514 nm line) to allow the measured fluorescence to
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reach a steady state level. The shown FRAP data were corrected for background noise
and normalized to pre-bleach values.
Apurinic/apyrimidinic (AP) endonuclease activity assay: A 75-mer oligonucleotide
containing AP site analog tetrahydrofuran (THF) at nucleotide 37 (Midland Corp) was 5′end-labeled with Cy5. Labeled oligo was annealed to the complementary strand with G
residue opposite THF.

This THF-containing duplex oligomer was incubated with

recombinant WT-APE1 or recombinant AcAPE1, in a 15 μL reaction mixture containing
50 mM Tris-HCl pH 8.5, 50 mM KCl, 1mM MgCl2, 1 mM DTT, 0.1 mM EDTA and 100 μg/
mL bovine serum albumin at 37 º C for increasing time points during which the reaction
rate was linear as described earlier(104, 133). The reaction was stopped with 10 μL 80%
formamide/40 mM NaOH containing 0.05% xylene cyanol, followed by heating at 95 °C
for 5 min. The samples were run in a 20% polyacrylamide containing 8M urea denaturing
gel electrophoresis to separate the substrate oligomer from the cleaved product. The gel
was visualized in odyssey Li-cor machine.
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3.3 Results
Genome-wide mapping of endogenous AP site damage and binding of repair
proteins.
We set out to elucidate the relationship between endogenous base damage and
formation of G4 structures in the genome. We first mapped the genome-wide occurrence
of AP sites, the most prevalent type of endogenous DNA damage in cells, which is
generated spontaneously or after cleavage of modified bases including oxidative or
alkylated G in the BER pathway (134, 135). We developed a technique to map genomewide AP site damage (AP-seq; Fig. 1A) at approximately 300 bp resolution in the
genome.
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Figure 1: Genome-wide mapping of endogenous AP site damage by AP-Seq and
binding of repair protein APE1 and AcAPE1. A) Top, schematic of AP-seq, designed
to detect apurinic-sites (AP-sites) in the genome. AP-sites are captured using a biotintagged aldehyde reactive probe (ARP) which specifically recognizes AP-sites (100, 136)
and pulled down with streptavidin. The enriched DNA is processed for sequencing and
mapped to reference genome. The damage level across genome is quantified by
analyzing the number of mapped reads. Bottom, schematic of Repair-seq, strategy to
map genome-wide binding enrichment of APE1 and AcAPE1 by ChIP-seq. B)
Representative region of chromosome 8 showing AP site occurrence and AcAPE1
binding profiles compared to IgG in control HCTT16 and isogenic HCT116 expressing
APE1 shRNA (APE1-KD) cells. The purple box highlights the disappearance of AcAPE1
peaks in APE1 KD cells.
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We found a reproducible occurrence of AP site damage in 21,228 and 22,314 regions
(p<0.0001) in the genome of lung adenocarcinoma A549 and colon carcinoma HCT116
cells respectively (Fig. 2A and 1B). Furthermore, to examine whether APE1, the primary
enzyme responsible for repairing the AP sites, binds to these regions, we also mapped
genome-wide occupancy of APE1 and Acetylated APE1 (APE1 is acetylated (AcAPE1)
at AP site damage in chromatin (137), by ChIP-Sequencing (repair-seq; Fig. 1A)
analysis in A549

and HCT116 cells, using α-APE1, α-AcAPE1 antibodies (Abs).

Multiple ChIP-Seq data analyses revealed ~ 24894 and 25904, (p<0.0001) APE1 and
AcAPE1-enriched peaks respectively (Fig. 2A and 1B). The disappearance of AcAPE1
binding peaks in HCT116 cells expressing APE1-specific shRNA compared to isogenic
wild type (WT) HCT116 cells (Fig. 1B), confirms the specificity of APE1 binding. A
significant (p<0.0001) overlap between AcAPE1 binding peaks (repair-seq) and AP-seq
in multiple independent biological replicates in several cell lines suggest that generation
of these endogenous DNA damages are non-random, predominantly occurring in
specific regions and are primarily repaired by APE1-mediated BER pathway. Analysis of
endogenous AP site damage and AcAPE1 binding distribution relative to annotated
genomic features revealed predominant occurrence (̴ 60%) in the transcribed gene
regions (exon and intron) and gene promoter regions (2000 bp upstream (-) and
downstream (+) of the transcription start site (TSS)) (Fig. 2B). Interestingly, although
the promoter regions represent only a tiny fraction of the human genome, we observed a
significant fraction (̴ 10%) of AP site damage and repair protein binding, suggesting
predominant occurrence of AP site and APE1-binding in promoter regions relative to
gene body. The occurrence of AP site damages and binding of APE1 were significantly
higher in both upstream and downstream regions compared to TSS which have the
lowest AP site damage-repair enrichment (Fig. 2C). We further validated the formation
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of AP sites and binding of APE1 and AcAPE1 to MYC and P21 gene promoters with or
without induction of damage using Real-Time ChIP-PCR analysis (Fig. 2D). Consistent
with our ChIP-seq data, super-resolution (110 nm) structured illumination microscopy
(SIM) revealed that AcAPE1 localizes to specific regions in the genome that bear the
active enhancer marker H3K27ac and active promoter marker H3K4me3 (Fig. 2E).
Collectively, these results demonstrate that endogenous base damages are not
randomly distributed in the genome but are predominant at defined gene regulatory
(promoter/enhancer) regions.
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Figure 2: Genome-wide mapping of endogenous AP site damage and binding of
repair proteins A) Representative region of chromosome 12 showing the distribution of
AP site damages and binding profiles of APE1 and AcAPE1 in A549 cells with increasing
resolution, zooming in on KRAS gene. ARP untreated cells (Neg. Ctrl.) or IgG were used
as controls. Layered H3K27Ac, H3K4Me1 (active enhancer), and H3K4Me3 (active
promoter) marks on seven cell lines from ENCODE shown in the bottom panel. The
purple box highlights the promoter region with co-occurrence of AP site damage and
repair protein APE1 and AcAPE1 binding. B) Gross genome-wide AP site occurrence,
APE1 and AcAPE1 binding is shown in the context of the promoter, gene-body, and
intergenic regions in A549 cell. C) Metprofiles of ~ 7500 protein coding genes showing
relative enrichment of AP site occurrence, APE1 and AcAPE1 binding distribution within
-/+ 2000 bp with respect to transcription start site (TSS). D) Validation of ChIP-seq data
for binding of APE1 AcAPE1 and ARP on P21 and MYC genes promoter regions in
A549 cells, by Real Time ChIP-PCR analysis. Methyl methane sulfonate (MMS), an AP
site damage-inducing agent, was used as a positive control. ****p<0.0001, ***p<0.001,
**p<0.01,

ns

p>0.05, calculated using unpaired t test. Error bars denote ±SD. E) 3-

Dimensional Structured Illumination Microscopy (SIM) images show co-localization of
APE1 or AcAPE1 with H3K27ac (active enhancer) and H3K4Me3 (active promoter) in
A549 cells; counterstained with DAPI. Pearson coefficient was calculated (n=10 cells) as
an indicator of colocalization frequency. F) AcAPE1-bound promoter sequences were
analyzed for finding de novo transcription factor (TF) binding motifs. Highly enriched
motifs are shown with corresponding TF binding site.
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Genome-wide mapping of occurrence of oxidative base damage and G4 structure
formation.
Analysis of promoter sequences occupied by AcAPE1 showed enrichment of G-rich
sequence motifs containing putative binding site of many transcription factors (TFs) (Fig.
2F). Since G residues in PQS are susceptible for oxidation by endogenous oxidants and
8-oxoG is primarily removed by OGG1(123, 138), we mapped genome-wide binding of
OGG1 using our previously generated acetylated OGG1 (AcOGG1) antibody (61) (Fig.
3A). AcOGG1 peaks are predominantly localized to gene promoters and overlap with
APE1 and AcAPE1 peaks (Fig. 3A). This raises the possibility that formation of 8-oxoG
in these regions recruits OGG1 which cleaves 8-oxoG, generating an AP site, and
recruits downstream BER enzyme APE1. With the help of QGRS (a web-based server
for G quadruplex prediction) mapper(139), we found 67% of AcAPE1 bound promoter
sequences to have a PQS score higher than 40 (PQS score >20 is considered as
significant).

To examine the relationship between AP site damage, binding of repair

proteins and G4 formation, we mapped genome-wide occurrence of G4 structures using
an antibody generated against G4 structure (BG4)(120, 140).

We found that G4

structures are enriched in the promoter, 5’ UTR and gene body of transcribed gene
regions as observed earlier (113). Intriguingly, we found a significant (p<0.0001)
genome-wide association between AP site damage, AcAPE1, AcOGG1 occupancy and
G4 structures formation across the whole genome including many promoter regions that
are known to form G4 (Fig. 3B and 3C). Overall, high Pearson correlation (r=0.64 and
r=0.69) was observed between G4 formation and APE1 or AcAPE1 across the genome
(Fig. 3C), particularly across +/- 2000 bp of TSS (Fig. 3D). Previously, QuadParser
analysis showed that the frequency of PQS are not equal between chromosomes as
some chromosomes are highly enriched with PQS irrespective of their sizes (141).
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Consistent with this, our chromosome-wise analysis reveals a positive correlation
between theoretically predicted PQS or experimentally observed G4s, and AcAPE1
binding peaks (Fig. 3E). High abundance of G4 structures in the promoter regions
throughout the genome and a significant overlap between G4 structures, AcOGG1 and
AcAPE1 in gene promoters (Fig. 3F) highlight a strong relationship between
endogenous oxidative base damage, associated repair complex with the formation of G4
structures and transcription. Many have reasoned gene promoters experience negative
super-helicity resulting from active transcription and that is sufficient to convert the
duplex DNA to a G-quadruplex on the purine-rich strand (142). If formation of G4
structures and endogenous damage and repair are coupled to active transcriptional
status, then inhibiting transcription would cause a concomitant shift in the binding of
repair proteins and G4 profiles. Thus, we inhibited transcription by Actinomycin D (143)
and performed APE1-seq, AcAPE1-seq, AcOGG1-seq, and G4 ChIP-seq. After inhibition
of transcription we found no significant alteration of APE1-seq or G4 ChIP-seq profile,
indicating that occurrence of AP sites or G4 is not dependent on active transcription and
it is not an indirect consequence of transcription (Fig. 3G). However, we found a
significant reduction of enrichment of sequences when we used acetylation-specific
antibody against AcAPE1 or AcOGG1 indicating acetylation of these proteins, but not
their promoter occupancy, is dependent on active transcription (Fig. 3G). We further
validated these observations by promoter-directed Real-Time ChIP-PCR analysis using
MYC and P21 sequence-specific primers. (Fig. 3H). Together, our genome-wide
association data provide the first experimental evidence that endogenous oxidative base
and/or AP site damage and BER initiating proteins (OGG1 and APE1) are predominantly
localized to specific G-rich transcriptional regulatory regions that can form G4 structures,
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suggesting a potential link between endogenous damage, activation of BER pathway
and G4 formation in vivo.
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Figure 3: Genome-wide mapping of occurrence of oxidative base damage and G4
structures. A) ChIP-Seq. analysis showing binding profiles of AcOGG1, APE1, and
AcAPE1 in A549 cells. B) Overlap of G4 structure, AP site damages and binding of
AcOGG1, APE1 and AcAPE1 in MYC, VEGF promoter regions (highlighted) that were
previously shown to form G4. C) Co-relation analysis was performed for genome-wide
enrichment of AcAPE1 and G4 structures. D) Metaprofiles of ~ 7500 protein coding
genes within +/- 2000 bp of TSS showing relative enrichment of G4, APE1 and AcAPE1
binding sites in A549 cells. E) Blue histograms represent predicted numbers of PQS/
106 bp mapped in the GRCH37/hg19 human genome by using QuadParser after
normalization of chromosome-size. Red and green histograms represent the observed
frequency of occurrence of G4 and AcAPE1 occupancy respectively, on each
chromosome by ChIP-Seq analyses. F) Venn diagram is representing overlapping p
romoters with AcAPE1, AcOGG1 and G4 enrichment (p<0.001). G) Metaprofiles of ~
7500 protein coding genes, in upstream of TSS, showing relative enrichment of G4,
AcOGG1, APE1 and AcAPE1 upon Actinomycin D (10 ug/ ml for 2 hours) treatment, in
A549 cells. H) Binding of APE1, AcAPE1, AcOGG1 and occurrence of G4 were
validated in P21 gene promoter upon Actinomycin D treatment by promoter directed
ChIP. ****p<0.0001, ***p<0.001, **p<0.01,
Error bars denote ±SD.

ns

p>0.05, calculated using unpaired t test.
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DNA repair function and acetylation of APE1 play a crucial role in the formation of
G4 structures in cells.
Having established a genome-wide correlation between base damage and G4 formation,
we asked the question whether APE1 plays any role in regulating the formation and/or
stability of G4 structures. G4 structures were visualized in human cells by confocal and
SIM microscopy by using G4 DNA-specific antibody 1H6 (128). We found the formation
of G4 foci in the genomic DNA of a number of human cell lines including primary lung
fibroblast IMR90, A549, HCT116, and Mouse Embryonic Fibroblast (MEF) cells (Fig. 4A,
5A, and 5B); formation of G4 foci was sensitive to DNase treatment, but did not change
upon RNase A treatment (Fig.4B), confirming its specificity in recognizing G4 structures
in genomic DNA.
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Figure 4: Visualization of G4 structures in cells and specificity of G4 antibody. A)
Lung fibroblast cells IMR-90 and mouse embryonic fibroblast (MEF) cells were
immunostained with G4 structure-specific antibody α-1H6, and α-APE1 Abs,
counterstained with DAPI and visualized by 3D SIM. B) A549 cells treated with RNase A
or DNase and immunofluorescence (IF) was performed using α-1H6, counterstained with
DAPI.
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We observed a high colocalization frequency (r=0.78) of G4 structures and APE1 or
AcAPE1 staining (Fig. 5A). Downregulation of APE1 levels by stable expression of
APE1shRNA in HCT116 cells abolished the formation of G4 foci compared to isogenic
WT HCT116 cells, indicating the critical importance of APE1 in regulating the formation
and/or stabilization of G4 structure in the genome (Fig. 5B). We further confirmed this
finding by transient downregulation of APE1 level with siRNA (Fig. 5B). We generated
HEK293T, HCT116, and A549 stable cell lines expressing two independent APE1shRNA
under a Dox-inducible promoter. Downregulation of APE1 levels in these cells with Dox
treatment showed a significant reduction in G4 foci formation suggesting the essential
role of APE1 in regulating the formation of G4 structures in the genome (Fig. 5C). No
change in staining of other proteins such as histone H3K27Ac mark further supports that
APE1 downregulation specifically reduced G4 staining (Fig. 5B). To further examine
whether binding of APE1 to AP site damages is essential for the formation of G4
structures, we treated HCT116 cells with methoxyamine (MX), a small molecule which
binds to AP sites and competitively inhibits binding of APE1 to AP sites both in vitro and
in cells (91). We found that pretreatment of cells with MX significantly inhibited the
formation of G4 structures suggesting that binding of APE1 to AP sites may be important
for promoting the formation of G4 structures (Fig. 5B). To test that whether OGG1 DNA
glycosylase which initiates the repair of 8-oxoG for generating an AP site also plays a
role in the formation of G4, we compared the G4 staining between WT MEF and OGG1-/MEF cells (144). Formation of G4 foci significantly decreased in OGG1-/- MEF (Fig. 5D).
As a non-BER related protein control we used adeno-Cre expressing ECD
(145) and found deletion of ECD gene by Cre expression did not change
formation in ECD

fl/fl

fl/fl

MEFs

G4 foci

MEFs (data not shown). These data together demonstrate that the

absence of either OGG1 or APE1 abolished the formation of G4 in cells, suggesting their
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critical role in the G4 formation. Furthermore, staining intensity of G4 foci increased in
live cells after exposure to G4 ligand pyridostatin (PDS) (141) which traps G4 structures
and stabilizes it in cells (Fig. 5E). However, G4-stabilizing ligand PDS had no effect on
the staining of G4 foci in same cells when APE1 was downregulated by shRNA or
siRNA, suggesting an essential role of APE1 in the formation of G4 structure in cells
(Fig. 5F).
APE1 is a multifunctional protein with DNA repair function (AP-endonuclease
activity) and redox-mediated transcription regulatory (Ref-1) function (40, 72).
Furthermore, several of our previous studies had shown that APE1 is acetylated at
multiple Lys (Lys6,7, 27, 31 and 32) residues at AP site damages in chromatin, and
AcAPE1 modulates both DNA damage repair and expression of genes via functioning as
a transcriptional activator or corepressor (55, 56, 62, 67, 83, 137, 146). To elucidate
which function of APE1 (DNA repair, redox or acetylation) is important for regulating the
G4 formation in cells, we ectopically expressed WT APE1, DNA damage repair defective
H309A (147), redox function deficient Cys65/Cys99S (40) and acetylation-defective K5R
(acetylabe Lys 6,7, 27,31 and 32 were mutated to arginine) (137) APE1 mutants in Doxinducible APE1 downregulated cells. Our data show that while expression of WT APE1
or redox mutant Cys65/Cys99 APE1 was able to restore the formation of G4 structures
in endogenous APE1-downregulated cells, both DNA repair-defective and acetylationdefective mutants failed to restore the formation of G4s in cells (Fig. 5G). Together,
these results suggest that presence of DNA glycosylase OGG1 and both APendonuclease function and acetylation of APE1 play a crucial role in the formation of G4
structures in the genome in cells.
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Figure 5: DNA repair function and acetylation of APE1 play a crucial in the
formation of stable G4 structures in the genome. A) Lung adenocarcinoma A549
cells were immunostained with G4 structure-specific antibody α-1H6, and α-APE1 or αAcAPE1 Abs, counterstained with DAPI and visualized by 3D SIM. Pearson coefficient
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was calculated (n=10 cells) as an indicator of colocalization frequency. B) HCT116 cells
transiently transfected with APE1siRNA or HCT116 cells constitutively expressing APE1
shRNA or cells treated with Methoxyamine (MX, 50 mM) for 30 mins were
immunostained α-1H6 and α-AcAPE1. HCT116siAPE1 cells were immunostained with αH3K27Ac and α-AcAPE1 as a control. C) HEK293T cells expressing a Doxycyclineinducible non-targeting shRNA control (NTCshRNA) and APE1-specific shRNA
(APE1shRNA) were treated with Doxycycline (2 ug/ mL) for 2 days and immunostained
with α-1H6 and α-AcAPE1. The level of APE1 in these cell extracts was examined by
Western blot analysis with α-APE1 and α-HSC70 (as loading control). D) Mouse
embryonic fibroblast cells established from OGG1 null-mice, OGG1-/- MEF and OGG1+/+
MEF were immunostained with α-1H6 and α-AcAPE1 and visualized by confocal
microscopy. E) HCT116 cells were pretreated with 1 uM of pyridostatin (PDS) for 1 hrs
and immunostained with α-1H6 and α-AcAPE1 and visualized by confocal microscopy.
F) HCT116 cells transfected with control siRNA (siCTL), APE1-specific RNA (siAPE1),
HCT116 cells constitutively expressing APE1 ShRNA (APE1shAPE1

) and HCT116

cells pretreated with MX (50 mM) 30 mins were subjected to PDS treatment for 1 hour
and immunostained with α-1H6 and α-AcAPE1 and visualized by confocal microscopy.
G) HEK-293T cells expressing APE1shRNA were treated with Doxycycline (2 ug/ mL) for
2 days to knockdown the APE1 levels and then cells were transfected with FLAG-tagged
WT APE1, or acetylation defective K5R (Lysine 6,7,27,31,32 mutated to arginine) or
repair defective H309A or redox defective C65,99S mutants of APE1 for 24 hrs and
immunostained with α-1H6 and α-AcAPE1 and visualized by confocal microscopy. The
level of APE1 in these cell extracts was examined by Western blot analysis with α-APE1
and α-HSC70 (as loading control).
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APE1 modulates G4-mediated expression of genes
To compare gene expression profile between control and Dox-inducible APE1 knockdown (APE1KD) A549 cells, we performed RNA-seq and focused on differentially
expressed (>2 -fold change) genes. We found that 31% of genes that are differentially
expressed in the absence of APE1 have both AcAPE1 binding and G4 structure
enrichment. Formation of G4 structure in the promoter region of many proto-oncogenes
such as MYC, KRAS, BCL-2 and its role in modulating their expression had been well
characterized in multiple studies (77, 148, 149). We found all these oncogene promoters
have endogenous AP site damage and AcAPE1 occupancy in A549 and HCT116 cells
(Fig. 6A). Thus, to understand the role of APE1 in G4-mediated gene transcription, we
took two oncogenes KRAS and MYC as a model in our study. We found significant
enrichment of APE1 or AcAPE1 and G4 in previously reported KRAS G4 promoter
region (148), but not in control non-G4 sequence region, by ChIP-qPCR with APE1 or
AcAPE1 and BG4 antibodies (Fig. 6B). Further, to establish whether APE1 is involved in
G4 folding in KRAS promoter, we performed ChIP-qPCR using α-BG4 in WT and
APE1KD cells. Quantitative PCR amplification revealed that loss of APE1 affects G4
enrichment on KRAS promoter regions compared to negative control regions (Fig. 6C
and 6D). Moreover, inhibition of APE1 acetylation by adenovirus E1A 12S (E1A inhibits
HAT function of p300, the acetyltransferase responsible for APE1 acetylation) (137)
protein overexpression also abrogated G4 enrichment in KRAS promoter (data not
shown) , indicating that APE1 and its acetylation is important for G4 folding. A recent
study has shown that specific G oxidation in PQS of KRAS promoter regulates KRAS
expression (148). Further, it was demonstrated that G4 sequence in KRAS promoter
facilitates the loading of several transcription factors including MAZ to the promoter
region (148). MAZ activates the transcription of KRAS through binding to (5′-
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GGG(A/C)GG) sites at the 5′ and 3′ ends of KRAS-G4 sequences. We examined the
role of AcAPE1 in the recruitment and binding of MAZ to the KRAS-G4 promoter. ChIPqPCR analysis in control or APE1KD cells showed decreased MAZ occupancy on
KRAS-G4 promoter in the absence of APE1 (Fig. 6C and 6D). Furthermore, oxidative
damage induction by Glucose Oxidase (GO) increased enrichment of G4, APE1 and
MAZ occupancy on KRAS-G4 promoter in WT cells but not in APE1KD HCTT16 cells
(Fig. 6E). To understand the role of oxidative damage and active BER pathway in G4mediated KRAS gene transcription, we did gene expression analysis by Real-time PCR
under various conditions. We found induction of oxidative damage by glucose oxidase
treatment increases KRAS gene expression in WT cells but not in APE1KD cells (Fig.
6F). Importantly, APE1KD attenuates both basal and oxidative stress-induced KRAS
expression (Fig. 6F). Further, we found that only ectopic expression of WT APE1 was
able to restore the KRAS gene expression, but neither the acetylation defective K5R
mutant nor the repair defective H309A APE1mutant was able to do so (Fig. 6G),
confirming again that both DNA repair function and acetylation of APE1 are necessary
for modulating the expression of KRAS.
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Figure 6: APE1 modulates G4-mediated expression of genes. A) Diagram shows
occurrence of AP site and AcAPE1 binding in G4 containing oncogene promoters. B)
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ChIP-Seq. analysis showing binding profiles and overlaps of occurrence of G4, AP site,
and binding of AcOGG1, APE1, and AcAPE1 on KRAS gene in A549 cells. The purple
box highlights AP site damage and repair protein AcOGG1, APE1, and AcAPE1 binding
in the established G4 positive promoter region. Bottom schematic represents KRAS G4
promoter region, that harbors binding site for MAZ transcription factor, and the green box
represents the

G4 and non-G4 regions

that were quantitated for examining the

enrichment for G4 and occupancy of MAZ TF by real-time ChIP experiments in Fig. C
and D. C) HCT116 cells and HCT116 constitutively expressing APE1 shRNA or D)
HCT116 cells expressing doxycycline-inducible APE1shRNA

cells showing the basal

G4 enrichment, MAZ enrichment in specific G4 region over non-G4 control region in
KRAS gene. The level of APE1 in these cell extracts was examined by Western blot
analysis with α-APE1 and α-HSC70 (as loading control). E) HCT116 control and
isogenic HCT116 shAPE1 cells were treated with glucose oxidase (GO) 50 ng/ml for 30
mins, ChIP qPCR was performed to examine APE1, BG4, and MAZ enrichment. F)
Expression of KRAS gene by Real-time PCR, normalized to GAPDH. The level of APE1
in these cell extracts was examined by Western blot analysis with α-APE1 and α-HSC70
(as loading control). G) HCT116 cells expressing APE1shRNA were treated with
Doxycycline (2 ug/ mL) for 3 days to knockdown the APE1 levels and then cells were
transfected with FLAG-tagged WT APE1, or acetylation defective K5R (Lysine 6,7,27,31
and 32 to arginine) or repair defective H309A mutants of APE1 for 24 hrs, and RT-PCR
performed to measure KRAS expression. ****p<0.0001, ***p<0.001, **p<0.01,
calculated using unpaired t test. Error bars denote ±SD.

ns

p>0.05,
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Our ChIP-seq data show enrichment of APE1 or AcAPE1 and G4 structures

in

previously reported MYC G4 promoter region (150) (Fig. 3B). To examine the role of
APE1 in regulating G4-mediated gene expression, we utilized promoter-luciferase
reporter with wild-type c-MYC (Myc- WT) G4 sequence in the upstream of promoter
region of firefly luciferase coding gene. The expression of c-MYC firefly luciferase was
normalized to relative expression of renilla luciferase gene from a non-G4 promoter
sequence (pRL-TK). We found induction of oxidative damage by hydrogen peroxide
activated Myc- WT luciferase expression in WT cells but not in APE1KD cells (Fig. 7A).
Importantly, APE1KD attenuates both basal and oxidative stress-induced Myc-WT
luciferase activity (Fig. 7A). c-MYC promoter PQS sequence has five G tracks and was
shown to form two alternate G4 structures in vitro utilizing four G-tracks either 2345 or
1245 (Fig. 7B) (142, 150, 151). Next, to confirm whether the effect of APE1 on gene
expression is mediated thorough the G4 sequence, we introduced two separate mutation
in c-MYC G4 sequence of the promoter-luciferase reporter i) Myc- G12A (G to A
mutation in 12th position of c-MYC G4; which can generate Myc 1245 G4 structure only),
ii) Myc-G18A (G to A mutation in 18th position of c-MYC G4; which cannot generate any
G4 structure) in the upstream region of firefly luciferase coding gene. Our results
demonstrate that Myc-G12A (Myc 1245-G4) has increased luciferase activity whereas
Myc-G18A (mutant G4) showed drastically reduced expression relative to Myc-WT
indicating G4 structure (specifically Myc 1245) is involved in induction of promoter
activity (Fig. 7C). Consistent with these results, downregulation of APE1 level in cells
reduced (~4-fold) Myc-WT and (~2-fold) Myc-G12A luciferase expression but did not
significantly affect Myc-G18A mutant G4-luciferase expression (Fig. 7C). . Overall, the
results suggest that APE1 alters MYC or KRAS gene expression via promoting the
formation of G4 structures and facilitating transcription factor loading.
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Figure 7: APE1 regulates G4-mediated MYC gene expression. A) MYC promoterluciferase reporter containing wild-type G4 sequence; Myc-WT and pRL-TK-renila
luciferase were co-transfected in control HCT116 cells or HCT116 cells transiently
transfected with APE1 siRNA (siAPE1) or HCT116 cells constitutively expressing APE1
shRNA. 48 hrs after transfection, cells were treated with H2O2 1 mM for 1 hour and
luciferase activity was measured and normalized with renila luciferase. The level of
APE1 in these cell extracts was examined by Western blot analysis with α-APE1 and αHSC70. B) Sequence of G4 forming Nuclease Hypersensitive element III1 (NHEIII1)
element of c-Myc gene (150). Bases are numbered according to the sequence of
NHEIII1. Two alternative G4 folding patterns (Myc 1245 and Myc 2345) of NHEIII1 are
shown. C) Promoter luciferase constructs of Myc-WT, Myc promoter harboring G to A
mutation in 12th G position (Myc-G12A) and in 18th position (Myc-G18A) in G4 sequence
were transfected in control or doxycycline inducible HCT116APE1shRNA

cells. Firefly

luciferase activity was measured and normalized with renilla luciferase activity. The
level of APE1 knockdown in these cell extracts was examined by Western blot analysis
with α-APE1 and α-HSC70. ****p<0.0001, ***p<0.001, **p<0.01,

ns

p>0.05, calculated

using unpaired t test. Error bars denote ±SD. D) 28-mer oligo sequences containing cMyc G4 forming sequence with AP site analog (THF) are shown. Circular Dichroism
(CD) spectra of WT-Myc , Myc G12AP, Myc G12AP, G18AP at 20 °C in presence or
absence of 100 mM KCl. The ordinate indicates the ellipticity signal expressed in mdeg.
E) CD spectra of Myc G12AP, Myc G12APG18AP at 20 °C in the presence of 100 mM
KCl or 1 ug of APE1 alone or both APE1 and KCl together. F) Electrophoretic mobility
shift assay was carried out to analyze binding of increasing amount (6.4, 64, 640 ng) of
recombinant APE1 (rAPE1) to Cy5-labeled AP site containing Myc duplex (DS) or G4
oligonucleotide substrates.
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Binding of APE1 to AP site damage in PQS promotes the G4-folding and
acetylation of APE1 enhances residence time.
Finally, we investigated the mechanistic connection between AP site damage in PQS,
binding of APE1 and formation of a stable G4 structures using c-MYC promoter G4
element. We performed in vitro studies using a 28-mer c-MYC promoter G4 (WT Myc) or
containing a single AP site analog, tetrahydrofuran, in the 3rd G track (Myc G12AP) or
two AP sites in the 3rd and 4th G track (Myc G12AP,G18AP) (Fig. 7D). We performed
circular dichroism (CD) spectroscopy to determine the secondary structure of DNA (152,
153). The presence of a strong positive peak at 2
̰ 65 nm with a weak negative signal at
240 nm is indicative of parallel G4 structure (154, 155). We found that KCl increased the
folding of c-MYC oligo to a stable G4 structure in vitro when a single AP site (Myc
G12AP) was present or absent (WT Myc) in the oligo (Fig. 7D). However, G4 oligo with
AP sites in both the 3rd and 4th G track (Myc G12AP, G18AP) was unable to form G4
structure in the presence of KCl, which served as a negative control. To test whether
binding of recombinant APE1 (rAPE1) at AP site in PQS can induce the formation of
stable G4s, we incubated Myc G12AP and G12AP,G18AP oligos with increasing doses
of recombinant APE1 in the absence of KCl. Addition of APE1 stimulated the folding of
Myc G12AP oligo to a G4 structures even in the absence of KCl suggesting that APE1
binding promotes the formation of G4 folding in vitro (Fig. 7E). Moreover, the presence
of rAPE1 and KCl together further enhanced the formation of G4 structure in vitro (Fig.
7E). In contrast, binding of APE1 to AP sites in Myc G12AP, G18AP oligo which cannot
form G4 showed no effect on CD signals. We compared binding affinity of APE1 to AP
site containing c-MYC duplex (DS) vs. pre-formed G4 oligo by EMSA assay. We found
that recombinant APE1 has equal affinity for binding to the AP site when present in
duplex or quadruplex forms (Fig. 7F).
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Figure 8: Binding of APE1 to AP site damage in PQS promotes the G4-folding and
acetylation of APE1 enhances residence time. A) Comparison of endonuclease
activity of recombinant APE1 or AcAPE1 on a Cy5-labeled 75-mer c-Myc duplex (DS) Vs
quadruplex DNA (G4) (substrate, S). A 37-mer long cleaved product (P) was shown at 2
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and 10 min. time points. B) Comparison of time-dependent cleavage activity of
recombinant APE1 Vs. AcAPE1 on a Cy5-labeled 75-mer c-Myc quadruplex DNA
(substrate, S). A 37-mer long product (P) was shown at different time points.
Quantitation of the average cleaved product from three independent experiments are
shown. C) FRAP analysis of GFP-APE1WT and GFP-APE1RR expressing cells was
performed with or without 1 mM MMS treatment for 30 minutes. Each point represents
the average of n=15 cells. Experiments were repeated at least three times and
consistently showed similar mobility differences. D) Schematic representation of how
binding of APE1 to AP site containing PQS sequence in the genome promotes folding of
G4 and regulate transcription. G4 motif sequences (GnLGnLGnLGnLGn; where n≥3 and
L is loop region containing any nucleotide) in PQS exits in a rapid equilibrium between
duplex-quarduplex forms. Upon G oxidation, 8-oxoG base damage initiates the BER
pathway and generates an AP site. Presence of AP site and subsequent binding of
APE1 shifts the equilibrium to form a stable G4 structure. Subsequent acetylation of
APE1 enhances its residence time on G4 and facilitates spatiotemporal stabilization of
G4 structure, promotes transcription factor loading and gene expression.
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The interaction between APE1 and AP site was previously studied in vitro in the G4
context, and it was found that APE1 binds AP sites in G4, but the cleavage rate was
attenuated (151). Consistent with this, we also found that rAPE1 cleaves AP site less
efficiently when it is present in G4 (Fig. 8A). We have recently shown that APE1 is
acetylated after binding to AP site in chromatin (137) and our current study shows that
both acetylation and DNA repair functions are essential for stable G4 (Fig. 5H) formation
in cells. Therefore, we examined the effect of acetylation on endonuclease function of
APE1 on G4 substrate. Recombinant AcAPE1 (rAcAPE1) had similar activity compared
to unmodified rAPE1 when the AP site is present in folded G4 structure (Fig. 8A and
8B). However, its was shown earlier that APE1 remains bound to cleaved AP site and
coordinate recruitment of downstream BER enzyme polymerase β (32, 95). To test
whether acetylation of APE1 increases its residence time at AP site damages in
chromatin in cells, we measured protein mobility at damage site by performing
fluorescence recovery after photobleaching (FRAP) assay with WT APE1 and Lys 6 & 7
acetylation defective RR-APE1 GFP mutants with or without inducing AP site damages
in cells. We found WT- APE1 GFP protein has higher residence time at damage site with
less mobile fraction than non-acetylable RR-APE1 GFP in control or MMS treated cells
(Fig. 8C). This suggests that acetylation may delay or slowdown the complete repair of
AP site and increase the residence time of APE1 in G4 structure to coordinate
transcriptional activation or repression via regulating loading of transcription factors to
promoters. Consistent with this, our ChIP-seq data show several transcription factors
binding site in AcAPE1 enriched promoter sequences (Fig. 2F), and AcAPE1 was shown
to co-occupy with many transcription factors and coactivators in the promoter regions
(31, 156, 157). Overall, the data suggest that binding of APE1 to AP site in PQS
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promotes the folding of G4 structures and acetylation of APE1 enhances its residence
time in chromatin which may spatiotemporally coordinate transcription and repair.

3.4 Discussion
Over the last few years, increasing direct evidence for the presence of G4 structures in
vivo has started to provide insights in G4 occurrence and their functions in controlling
multiple biological processes including transcription, replication, translation and telomere
maintenance (117, 119, 158).

Aberrant regulation of G4 structures are detrimental,

causing transcriptional deregulation, replication stress, genome instability and human
diseases (116). Understanding of how the formation (folding) and stabilization of G4s in
the genome are regulated is fundamentally important. In this study, by conducting
unbiased genome-wide mapping we demonstrate that the occurrence of endogenous
base damage and APE1 binding is not random and are predominant in G4 sequences.
Importantly, we demonstrate that endogenous oxidative base damage in G4 sequences
and subsequent activation of BER drive the spatiotemporal formation of G4 structures
which in turn regulate gene expression via facilitating transcription factors loading. Our
study reveals a regulatory role of

the BER machinery in coordinating the formation of

higher order DNA secondary structures (G4s) in the genome.
Oxidatively induced endogenous DNA damage is conventionally viewed as detrimental
to cellular processes. However, several recent studies have shown that oxidative DNA
damages have a strong positive correlation with elevated oncogene expression (159).
An interplay between oxidative-stress signaling, formation of 8-oxoG, binding of OGG1
and APE1 in promoters, and transcriptional activation or repression has been
documented in mammalian genes (160-168). Moreover, recent studies have
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demonstrated that 8-oxoG or AP sites when present in G4-forming promoter sequences
of VEGF, BCL-2, and KRAS, directly upregulates transcription of the downstream genes
(77, 148, 157, 164). Of note, these G4-promoter containing genes are known to be
regulated by oxidative stress (169).

Our study provides a mechanistic framework by

highlighting a connection between oxidative base damage and the ability of certain DNA
sequences to fold into G4 to regulate transcription.
We propose that PQS in the genome exists in a dynamic equilibrium between duplex
and quadruplex forms and that guanine residues in PQS are oxidized to form 8-oxoG by
cellular oxidants through intrinsic or extrinsic signal-dependent manner. Formation of 8oxoG base damage in PQS recruits OGG1 to initiate the BER pathway (Fig. 8D). Our
genome-wide overlap of OGG1 binding peaks with G4 support this (Fig. 3B). It was
shown that unlike 8-oxoG paired with C, AP site in duplex DNA significantly impact the
thermal stability of duplex DNA (164, 170, 171). We propose that cleavage of 8-oxoG
and generation of AP site by OGG1 in PQS destabilizes it and opens up the duplex (172,
173), allowing the PQS to adopt an G-quadruplex fold where AP site containing G patch
is looped out. This new conformation facilitates the binding of APE1 to AP sites for
stabilizing G4 structure. Consistent with this, our in vitro CD-spectra data shows that the
presence of an AP site and binding of APE1 in MYC PQS oligo promotes the formation
of G4 structures in vitro (Figure 7E). These observations support a mechanism by which
the AP site facilitates G4 formation by shifting the duplex-quadruplex equilibrium, and
subsequent binding of APE1 to the AP sites promotes the formation of a stable G4
folding. However, we do not know the exact molecular basis of how APE1 binding
promotes the stability of G4 folding. It is likely that APE1 binding increases the thermal
stability of G4 structure. Alternatively, APE1 binding to G4 prevents the binding of G4resolving helicases and thus spatiotemporally stabilize the G4 structures to regulate
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transcription. Further, in vitro thermodynamics, DMS foot printing, and helicase activity
studies are necessary to delineate the mechanistic details. We propose, oxidative DNA
lesions at G4 sequences act as a sensor and initiation of BER pathway is intermediate in
a signal transduction cascade that regulate G4 structure to ultimately modulate
transcription. In a previous study, Fleming et al. (164) demonstrated that the fifth G-track
of the VEGF PQS helped to reconstitute a G4 structure when one of the four upstream
G-track contained a damaged base or AP site which induced VEGF transcription. Of
note, most of the oncogenes that are regulated by G4 structure have promoter PQS with
five or more G patch (149). Promoter G4s are more conserved than other regions
according to the mining of human genome sequence analysis(174, 175). Evolutionary
selection of such oxidative damage prone G rich sequences (G4) in the genome and
their role in gene regulation suggest a novel oxidative damage signaling mechanism
where BER co-ordinates the process through modulating DNA secondary structures
(G4s) and maintaining the integrity of the regulatory sequences.
Consistent with our model, cell-based assays show that initiation of repair of 8-oxoG via
BER plays a crucial role in the formation of stable G4s. Our data show that the loss of
either the initial glycosylase, OGG1 or the downstream repair protein APE1, abolished
the formation of G4 structures in cells (Fig. 5B, 5C, and 5D). The observations that loss
of either the endonuclease activity or acetylation of APE1 abrogates G4 formation raises
the questions about the biological importance of these functions of APE1 in the
formation of G4. We propose that APE1 cleaves the AP site and remains bound to G4
structures. APE1 is then acetylated by histone acetyl transferase p300, commonly found
in promoters and enhancers of the gene via its association with TFs or RNA Pol II (56).
This spatiotemporal acetylation of APE1 delays its dissociation from AP sites and
stabilizes G4 structures; APE1 is then well positioned to stimulate binding of TFs, which
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activates transcription. Consistent with this, our data show that knockdown of APE1 or
inhibition of its acetylation abrogates G4 formation and reduced MAZ1 TFs loading on
the KRAS promoter. Such a mechanism explains why AcAPE1 has increased residence
time in chromatin (Fig. 8C), interacts with many TFs in the promoter region (31, 55, 56,
67, 68, 83), and AcAPE1- bound regions significantly overlap with G4 structure and bear
active enhancer and promoter histone marks. Many reports have found co-occupancy
and interaction of APE1 with activating or repressor factors such as STAT3, HIF-1α, AP1, NF-κB, and HDAC1at promoter regions (31, 39, 156, 157). The present data, in
tandem with our previous studies, support AcAPE1 coordinates both DNA damage
repair and transcription.
Although this study shows that G4 structure formation is coupled with endogenous
oxidative DNA damage followed by activation of BER pathway, the source of an
essentially site-specific G oxidation or base damage in PQS promoter sequence in the
genome remains a question. Random oxidation of G is too erratic to constitute the
mechanism. However, we have observed reproducible occurrence of AP sites or
enrichment of OGG1 and AcAPE1 binding to specific regions of active genes in multiple
independent experiments in multiple cell lines. This discovery raises one intriguing
question about whether endogenous oxidative or AP site damages occur in a targeted or
site-specific manner (167). Although few recent studies have shown region-specific
distribution of DNA damages (176, 177), further high-resolution (single-base) mapping of
base damage in the genome is warranted. Eliciting a targeted DNA base damage
appears to be a common first step in hormone-induced activation of many genes. For
example, Perillo et al.(161) have shown that estrogen-induced activation of BCL-2 gene
occurs by flavin-dependent demethylation of H3K9me2 by LSD-1 in the promoter region
of BCL-2 gene which generates H2O2. This local oxidation was shown to produce G
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oxidation in the promoter of BCL-2 gene in a targeted manner. Interestingly, BCL-2
promoter regions contain PQS (77). They found LSD1-mediated oxidation in PQS and
noted an essential role of OGG1 of BER in the activation process. Pan et al.(162) have
also shown that oxidation of G in NF-κB binding site promotes NF-κB binding and
stimulates transcription. Similarly, active demethylation of 5-methylcytosine by TET
enzymes also produce H2O2 and excision of deaminated 5-meC (Thymine) by the BER
glycosylases TDG1 are thought to play a key role in the transcriptional control and
resetting of epigenetic memory during embryonic development and cellular programing
(178). However, further studies are necessary to address how an indiscriminate oxidant
like H2O2 liberated by LSD1 generates specific G oxidation in PQS sequences to induce
G4 formation.
G4 structures are often formed in the 3' overhang regions of telomere sequences(112,
179-181) and can serve regulatory roles by protecting telomere cap structures (113,
117). A corollary to our study, Mandler et al.(73) has shown that both DNA repair and
acetylation of APE1 are essential for maintaining telomere length and absence of either
function of APE1 leads to telomere shortening, telomere fusion and formation of micronuclei in cell lines, perhaps de-stabilizing the G4 structure in telomere. G4-induced
replication stress, DNA damage and genomic instability have been linked with many
cancers (115, 116, 118). Mutations or loss of many G4 resolving helicases, such as
WRN, ATRX and DDX21 are indicated to cause genome instability and disease
pathology (122).

Studies have found that G4 forming sequences are enriched at

translocation breakpoints (182).

Moreover, an expandable GGGGCC motif that can

adopt a G4 structure, located in many gene locus, have been found to contribute to two
well recognized neurodegenerative diseases, amyotrophic lateral sclerosis (ALS) and
frontotemporal dementia (FTD) (116, 183). We propose that endogenous oxidative
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damages and the activation of BER not only repairs damaged bases but also regulates
the formation and stability of G4 structures in the genome to regulate multiple biological
processes. It is noteworthy to mention that like G4 structures, crucial roles of the BER or
APE1 in regulating multiple biological processes, ranging from transcription, maintaining
telomere length, class-switch recombination, somatic hypermutation, and mRNA
biogenesis has been demonstrated (34, 76, 127, 184-186). Our study introduces a new
perspective in understanding that region-specific endogenous damage and activation of
BER serve specific functions in regulation of G4 for controlling multiple cellular
processes. This function of endogenous damage and the BER machinery defines a new
role, beyond its well characterized role as a safeguard for maintaining genomic integrity
and preventing mutations, dysregulation of which can lead to many human diseases.
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CHAPTER 4

Overall conclusions and future directions
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5.1: Overall conclusions
My dissertation was aimed at improving the understanding of the functional role of APE1
acetylation in DNA repair and transcription regulation. Characterization of AcAPE1 is
important to understand the reason behind its upregulation in different cancers and
necessity for cell survival and proliferation. It is well established that the C-terminal
domain of APE1 is important for DNA repair function (7). However, the direct functional
significance of its N-terminus and acetylation is still under investigation. Although
acetylation was associated with APE1’s transcription regulatory function, the underlying
mechanism was not very clear (31). Thus, elucidating the underlying functions of
AcAPE1 may provide sight for generating future cancer drug targets.
Towards that end, the work presented in chapter 2 of this dissertation has
demonstrated that AcAPE1 is exclusively localized to chromatin in all phases of the cell
cycle, including mitosis. Genotoxic stress induces acetylation and APE1 is acetylated at
AP site in chromatin (63). Although the N-terminal domain (aa 1 to 40) of APE1 is known
to be dispensable for its in vitro DNA repair activity, our study demonstrated the novel
regulatory role of acetylation of multiple lysine residues in this domain in AP site repair
both in vitro and in cells. Using Acetylation defective mutants, we found the absence of
acetylation in cells expressing APE1 results in the accumulation of AP sites in the
genome, and the genome becomes sensitive to DNA-damaging agents. Our data
suggested acetylation not only improves the catalytic efficiency of APE1 but also may
facilitate the coordination and recruitment of the downstream enzyme in the BER
pathway. Collectively, the acetylation of APE1 is likely an integral part of the APE1dependent BER pathway for maintaining DNA integrity.
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In chapter 3 of this dissertation, to know the genome-wide distribution of APE1,
AcAPE1, we conducted an unbiased mapping of AP sites, APE1, and AcAPE1 binding
across the genome, we provide the first direct evidence that the occurrence of
endogenous base damage and APE1 binding is not random. There are distinct patterns
of AP sites, APE1, and AcAPE1 binding predominantly in the transcription regulatory
regions and specifically in G-quadruplex (G4) sequences in the genome. Formation of
G4 DNA structures in key regulatory regions (gene promoters, 5’ and 3’ untranslated
regions and telomeric regions) in the genome has emerged as a secondary structurebased epigenetic mechanism for regulating multiple biological processes including
transcription, replication, translation, and telomere maintenance (110, 113). Aberrant
regulation

of

G-quadruplex

structures

are

detrimental,

causing

transcriptional

deregulation, genome instability, and human diseases (116). For biological functions,
formation, stabilization, and unfolding of G4 must be spatiotemporally regulated. While
several proteins that bind to and resolve G4 structures have been characterized, the
mechanisms underlying spatiotemporal formation and stabilization of G4 structures in
the genome are largely unknown. We comprehensively demonstrated that APE1, a key
player in BER, is directly involved in the spatiotemporal regulation of G4 structures in the
genome. This study shows that oxidation of G and the resulting AP site recruits APE1
which shift the duplex-quadruplex equilibrium to the G4 fold. This, in turn, promotes the
formation of stable G4 structures and regulate gene expression via facilitating
transcription factor loading to the promoter. Loss of APE1 or its acetylation abrogates
the formation of G4 structures in cells. APE1 binding promotes G4-folding in-vitro, and
acetylation of APE1 which enhances its residence time stabilizes G4 structures and
facilitates transcription factor loading on promoters, providing mechanistic insight into the
role of APE1 in G4-mediated gene expression. Our study unravels an acquired function

97

of endogenous base damage and BER in controlling the formation of higher order DNA
secondary structures beyond its role in safeguarding the genomic integrity.
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5.2 Future directions
5.2.1 Role of acetylated APE1 in mitotic DNA damage bookmarking
According to the classical concept, mitotic chromosome condensation is coupled with
the cessation of transcription with dissociation of most sequence-specific transcription
factors (187-189). However, recent studies have revealed the presence of open
chromatin structures associated with active gene histone mark and presence of some
regulatory proteins during mitosis in those regions (190). This novel epigenetic
mechanism is thought to control the post-mitotic gene expression pattern. Although
repair is not active during mitosis, but damage can occur to these open chromatin
regions specifically in active gene enhancer-promoter regions (191). Recently, selective
mitotic retention of regulatory proteins in the promoter-enhancer region, a phenomenon
called mitotic gene bookmarking, has changed the dogma about mitosis (192). Thus,
subsequent marking of these DNA damages and preferential repair of these regions is a
prerequisite for stable TF-binding or RNA Pol II-loading to restore rapid post-mitotic
activation of the genes. High proliferating cells, specifically tumor cells, will be benefitted
by this kind of epigenetic mechanism that would facilitate rapid gene activation following
mitotic exit. However, the major gap in our understanding is that how cells bookmark
DNA damages in mitosis and preferentially repair these regions for post-mitotic
reactivation of gene.
We discovered that AcAPE1 is exclusively associated with chromatin and
remains bound to the condensed chromatin at all stages of mitosis. Our genome-wide
binding analysis showed binding of AcAPE1 to selective regions (promoters and
enhancers) of several thousands of active genes and persist throughout mitosis.
Madlener et al. recently showed loss of either repair activity or Lys 6,7 acetylation leads
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to telomere fusion and mitotic defects (73). It is important to elucidate the role of APE1
acetylation, BER status in mitosis, and the functional importance of sequence selective
AcAPE1 retention in the mitotic chromosome. Understanding the role of pre-exiting
AcAPE1 in selective regions in the chromosome in mitosis may reveal a novel function
of AcAPE1 in mitosis and the pathophysiological importance of elevated AcAPE1 in
cancer cells that are continuously undergoing through mitosis.
5.2.2 Mechanistic insight into the role of AcAPE1 in G-quadruplex formation and
stabilization
The multitude of G4 regulated cellular processes extending in both DNA and RNA level
highlights the presence of a tightly coordinated epigenetic mechanism, just like CpG
methylation and histone modification (113). Instead of writer, reader, and eraser
proteins, there must be signal dependent formation (folding), stabilization, and unfolding
to regulate a biological function. Many helicases have been documented to resolve G4
structure to coordinate G4 mediated cellular function such as WRN, BLM and ATRX in
telomere maintenance, Pfh1 and FANCJ in replication fork progression, XPD/XPB and
WRN in transcription and DDX21 and DHS36 in translation and loss of these proteins
are indicated to cause genome instability and disease pathology (122). However, the
signals or the proteins regulating the structural shift of a double helix towards a G4 and
maintaining their spatiotemporal stability in cells are largely unknown.
Our genome-wide correlation of endogenous AP site mapping, APE1 binding and
G4 occurrence together with a causal effect of loss of APE1 in G4 formation and
stabilization, first time illustrates a mechanism behind G4 folding in cells. However, the
molecular necessity of base damage and BER in G4 formation is not clear. Further,
using in vitro biophysical (thermal stability, FRET, and CD) biochemical assays (binding
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kinetics, DMS and bromide foot printing), and G4 containing promoter reporter
approaches, future studies will elucidate the molecular basis of how APE1 promotes G4
folding. This information is important to understand the G4 folding/ stabilization dynamics
inside the cell to design targeted strategies.
As we found that acetylation of APE1 is essential for spatiotemporal G4
formation and G4-mediated gene expression. We have developed an APE1 Lys 6, 7
acetylation defective mouse model. This mouse model will be utilized to elucidate the
impact of compromised BER on G4 formation, gene expression, telomere maintenance
and mutation accumulation at G4-forming sequences in the genome. Our acetylationdefective mouse models have excellent potential for dissecting the relative importance of
acetylation of APE1 and efficient BER in regulating the formation of G4 structures and
perhaps illustrating the pathophysiological consequences of alteration of G4 mediated
gene expression and mutation accumulation in G4 sequence in vivo.
5.2.3 Intertwined role of DNA base damage repair and gene transcription in
mammalian cells
The mechanism of BER has been reconstituted in vitro and is well characterized (7).
However, a full understanding of AP site repair must take into account how it occurs in
live cells, where DNA is packed into chromatin and serves as a template for
transcription.

Genome-Wide

comparison

of

open

chromatin

status,

histone

modifications, RNA expression, and DNA damage and repair would allow determining of
how these processes are coordinated. Transcription, a DNA templated basic process
occurring in every cell, is mutagenic in nature (193). Nevertheless, considering the
inherent mutagenic nature of transcription and frequency at which DNA damage occurs
(~104 events per day), it is remarkable that the overwhelming majority of these
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deleterious DNA lesions are repaired with impressive accuracy and efficiency in
transcribed gene regions to avoid mutations. There is a reason to believe that
interdependency between transcription and DNA repair is finely regulated to orchestrate
this choreographed process. However, a clear mechanistic link between DNA damage,
repair, and transcription have not yet been established.
We have developed a genome-wide assay for mapping AP site damage
(damage-seq) and repair by APE1 and AcAPE1 (repair-seq) in cells. We are using
damage and repair-seq strategy to measure repair kinetics after Methylmethane
sulfonate (MMS); an alkylating agent known to produce AP sites, induced damage and
then related the kinetics of repair to chromatin state and transcription. Initial study shows
AP sites damage predominantly occurs to transcriptionally active regions. Of note, not all
APE1 binding sites overlapped with AcAPE1 sites indicating there are two pools of
APE1. Interestingly, inhibition of transcription inhibits APE1’s acetylation and alters
repair kinetics of the active gene regions. Further, analyzing the damage-repair
occurrence in context to different epigenetic features, transcription status will identify
fundamental interdependency between endogenous AP site damage-repair with
transcription.
Together, this dissertation research study have provided valuable molecular
insights into the role of acetylated APE1 in mammalian cells and warrant further studies
to delineate molecular networks and pathophysiological consequences of aberrant
regulation of APE1 N-terminal acetylation.
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